

FORM PTO-1390 (Modified) (REV 10-95)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER <div style="text-align: center; font-weight: bold;">BB-1395</div>	
<b>TRANSMITTAL LETTER TO THE UNITED STATES          DESIGNATED/ELECTED OFFICE (DO/EO/US)          CONCERNING A FILING UNDER 35 U.S.C. 371</b>				U.S. APPLICATION NO. (IF KNOWN, SEE 37.CFR) <div style="text-align: center; font-size: 1.2em; font-weight: bold;">10/069427</div>	
INTERNATIONAL APPLICATION NO. <div style="text-align: center; font-weight: bold;">PCT/US00/26442</div>		INTERNATIONAL FILING DATE <div style="text-align: center; font-weight: bold;">27 SEPTEMBER 2000 (27.09.00)</div>		PRIORITY DATE CLAIMED <div style="text-align: center; font-weight: bold;">30 SEPTEMBER 1999 (30.09.99)</div>	
TITLE OF INVENTION <div style="text-align: center; font-weight: bold;">GENES ENCODING STEROL DELTA-15 REDUCTASE IN PLANTS</div>					
APPLICANT(S) FOR DO/EO/US <div style="text-align: center; font-weight: bold;">FAMODU, Omolayo O. et al.</div>					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information					
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This is an express request to being national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b)) and PCT Articles 22 and 39(1).</li> <li>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19<sup>th</sup> month from the earliest claimed priority date.</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application was filed (35 U.S.C. 371 (c) (2))           <ol style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau.</li> <li>b. <input type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US)</li> </ol> </li> <li>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371 (c) (2)).</li> <li>7. <input type="checkbox"/> A copy of the International Search Report (PCT/ISA/210).</li> <li>8. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c) (3))           <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>9. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</li> <li>10. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).</li> <li>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409)</li> <li>12. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).</li> </ol>					
<b>Items 13 to 18 below concern document(s) or information included :</b>					
<ol style="list-style-type: none"> <li>13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>15. <input type="checkbox"/> A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.</li> <li>16. <input type="checkbox"/> A substitute specification.</li> <li>17. <input checked="" type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>18. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail.</li> <li>19. <input type="checkbox"/> Other items or information:</li> </ol>					
<div style="border: 1px solid black; padding: 5px;"> <p>17. General Power of Attorney</p> <p>18. Express Mailing Label No.: EJ376013603US</p> </div>					

APPLICATION NO. (IF KNOWN, SEE 37 CFR) **10/069427** INTERNATIONAL APPLICATION NO. **PCT/US00/26442** ATTORNEY'S DOCKET NUMBER **BB-1395**

20. The following fees are submitted

**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :**

- ☒ Search Report has been prepared by the EPO or JPO \$890.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) \$710.00
- ☐ No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$740.00
- ☐ Neither international preliminary examination fee paid to USPTO (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$1,040.00
- ☐ International preliminary examination fee paid to USPTO (37 CFR 1.482) And all claims satisfied provisions of PCT Article 33(2)-(4) \$ 100.00

**CALCULATIONS - PTO USE ONLY**

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

**\$890.00**

Surcharge of \$130.00 for furnishing the oath or declaration later than months from the earliest claimed priority date (37 CFR 1.492 (e)). ☐ 20 ☐ 30

**\$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	26 - 20 =	6 x	\$18.00	\$108.00
Independent Claims	3 - 3 =	6 x	\$84.00	\$0.00
Multiple Dependent Claims (check if applicable)			<input type="checkbox"/>	\$0.00

**TOTAL OF ABOVE CALCULATIONS =**

**\$108.00**

Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28) (check if applicable). ☐

**\$0.00**

**SUBTOTAL =**

**\$108.00**

Processing Fee of \$130.00 for furnishing the English translation later than months from the earliest claimed priority date (37 CFR 1.492 (f)). ☐ 20 ☐ 30

**\$0.00**

**TOTAL NATIONAL FEE =**

**\$998.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). ☐

**\$0.00**

**TOTAL FEES ENCLOSED =**

**\$998.00**

Amount to be refunded \$

Charged \$

- ☐ A check in the amount of \_\_\_\_\_ to cover the above fees enclosed.
- ☒ Please charge my Deposit Account No. **04-1928** in the amount of **\$998.00** to cover the above fees.
- ☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment to Deposit Account No. **04-1928** a duplicate copy of this sheet is enclosed.

**NOTE : Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (CFR 1.37(a) or (b)) must be filed and granted to restore the application to pending status.**

**SEND ALL CORRESPONDENCE TO:**

**GOLIAN, Paul D.  
E. I. DU PONT DE NEMOURS AND COMPANY  
Legal Patent Records Center  
4417 Lancaster Pike  
Wilmington, Delaware 19805  
United States of America**

SIGNATURE

**GOLIAN, PAUL D.**

NAME

**42,591**

REGISTRATION NUMBER

**2/8/02**

DATE

10 Rec'd PCT/PTO 16 JUL 2002

10/069427

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the Application of:

OMOLAYO O. FAMODU ET AL.

CASE NO.: BB1395 US PCT

APPLICATION NO.: 10/069,427

GROUP ART UNIT: UNKNOWN

FILED: UNKNOWN

EXAMINER: UNKNOWN

INTERNATIONAL APPLICATION NO.: PCT/US00/26442

INTERNATIONAL FILING DATE: SEPTEMBER 9, 2000

FOR: GENES ENCODING STEROL  
DELTA-15 REDUCTASE IN PLANTS

**STATEMENT UNDER 37 CFR 1.821(g) and 1.825(b)**


Commissioner for Patents, Box PCT  
United States Patent and Trademark Office  
Washington, DC 20231

Sir:

The submission of the substitute Sequence Listing filed concurrently herewith does not include new matter.

The copy of the substitute Sequence Listing in computer readable form filed concurrently herewith is the same as the paper copy of the substitute Sequence Listing filed concurrently herewith.

Respectfully submitted,



Lori Y. Beardell  
Attorney For Applicants  
Registration No. 34,293  
Telephone: 302-992-4926  
Facsimile: 302-892-1026

Dated: July 11, 2002

SEQUENCE LISTING

<110> Famodu, Omolayo O.  
Kinney, Anthony J.

<120> Genes Encoding Sterol Delta-15 Reductase in Plants

<130> BB1395 PCT

<140> 10/069,427

<141>

<150> 60/156,820

<151> 1999-09-30

<160> 10

<170> Microsoft Office 95

<210> 1

<211> 427

<212> DNA

<213> Glycine max

<220>

<221> unsure

<222> (360)

<223> n=a,c,g or t

<400> 1

```
gtgatgatgg agtcacacgt ggatctaggt tttctccttc aagctctcac tccatcttgg 60
aactccgttc ctttgcttgt ggggttcttc acttacttgg ccgttgctgg atccattctc 120
cctggaaaac ttgttctctg cgttgcaacta ctcgatggaa ctggtctaca ctattgctgc 180
aatgggtctgc tctcgcttct tctgttggtt gcacttctcg ggatcgggtgc caagatgggt 240
tttgtgtctc ccactgccat atcaaacaga ggacttgagc tgctgtccac aacttttgcc 300
ttcagttttc ttgtaaccct gatattgcat ttttcgggtt gcaagtcaca aagtaaaggn 360
tcatcactaa agcctcatct cagtgggaac ctgatacacg attggtgggt tgggaatata 420
actaaaa
```

<210> 2

<211> 126

<212> PRT

<213> Glycine max

<400> 2

```
Leu Gln Ala Leu Thr Pro Ser Trp Asn Ser Val Pro Leu Leu Val Gly
 1             5             10             15
Phe Phe Thr Tyr Leu Ala Val Ala Gly Ser Ile Leu Pro Gly Lys Leu
      20             25             30
Val Pro Gly Val Ala Leu Leu Asp Gly Thr Arg Leu His Tyr Cys Cys
      35             40             45
Asn Gly Leu Leu Ser Leu Leu Leu Val Ala Leu Leu Gly Ile Gly
      50             55             60
Ala Lys Met Gly Phe Val Ser Pro Thr Ala Ile Ser Asn Arg Gly Leu
```

65					70					75					80
Glu	Leu	Leu	Ser	Thr	Thr	Phe	Ala	Phe	Ser	Phe	Leu	Val	Thr	Leu	Ile
				85					90					95	
Leu	His	Phe	Ser	Gly	Cys	Lys	Ser	Gln	Ser	Lys	Gly	Ser	Ser	Leu	Lys
			100					105					110		
Pro	His	Leu	Ser	Gly	Asn	Leu	Ile	His	Asp	Trp	Trp	Phe	Gly		
		115					120					125			

```
<210> 3
<211> 1631
<212> DNA
<213> Glycine max
```

```
<210> 4
<211> 374
<212> PRT
<213> Glycine max
```

Ala Val Ala Gly Ser Ile Leu Pro Gly Lys Leu Val Pro Gly Val Ala  
35 40 45

Leu Leu Asp Gly Thr Arg Leu His Tyr Cys Cys Asn Gly Leu Leu Ser  
50 55 60

Leu Leu Leu Leu Val Ala Leu Leu Gly Ile Gly Ala Lys Met Gly Phe  
65 70 75 80

Val Ser Pro Thr Ala Ile Ser Asp Arg Gly Leu Glu Leu Leu Ser Thr  
85 90 95

Thr Phe Ala Phe Ser Phe Leu Val Thr Leu Ile Leu His Phe Ser Gly  
100 105 110

Cys Lys Ser Gln Ser Lys Gly Ser Ser Leu Lys Pro His Leu Ser Gly  
115 120 125

Asn Leu Ile His Asp Trp Trp Phe Gly Ile Gln Leu Asn Pro Gln Phe  
130 135 140

Met Gly Ile Asp Leu Lys Phe Phe Phe Val Arg Ala Gly Met Met Gly  
145 150 155 160

Trp Leu Leu Ile Asn Leu Ser Ile Leu Met Lys Ser Ile Gln Asp Gly  
165 170 175

Thr Leu Ser Gln Ser Met Ile Leu Tyr Gln Leu Phe Cys Ala Leu Tyr  
180 185 190

Ile Leu Asp Tyr Phe Val His Glu Glu Tyr Met Thr Ser Thr Trp Asp  
195 200 205

Ile Ile Ala Glu Arg Leu Gly Phe Met Leu Val Phe Gly Asp Leu Val  
210 215 220

Trp Ile Pro Phe Ser Phe Ser Ile Gln Gly Trp Trp Leu Leu Met Asn  
225 230 235 240

Ser Val Glu Leu Thr Pro Ala Ala Ile Val Ala Asn Cys Phe Val Phe  
245 250 255

Leu Ile Gly Tyr Met Val Phe Arg Gly Ala Asn Lys Gln Lys His Val  
260 265 270

Phe Lys Lys Asn Pro Lys Ala Pro Ile Trp Gly Lys Pro Pro Lys Val  
275 280 285

Ile Gly Gly Lys Leu Leu Ala Ser Gly Tyr Trp Gly Ile Ala Arg His  
290 295 300

Cys Asn Tyr Leu Gly Asp Leu Met Leu Ala Leu Ser Phe Ser Leu Pro  
305 310 315 320

Cys Gly Ile Ser Ser Pro Ile Pro Tyr Phe Tyr Pro Ile Tyr Leu Leu  
325 330 335

Ile Leu Leu Ile Trp Arg Glu Arg Arg Asp Glu Ala Arg Cys Ala Glu  
340 345 350

Lys Tyr Arg Glu Ile Trp Ala Glu Tyr Arg Lys Leu Val Pro Trp Arg  
355 360 365

Ile Leu Pro Tyr Val Tyr  
370

<210> 5  
<211> 667  
<212> DNA  
<213> Zea mays

<400> 5  
ccacgcgtcc ggaagaacaa agtagagctg tcccttttgt ctggtctagc taacttatgc 60  
atctttctta ttggctacct agtggtccga ggagctaaca agcaaaaaca tgtgttcaag 120  
aaggacccca agctccctat atggggaaaa cctcccaaag ttgtcggggg aaagctacta 180  
gcatctggtt actggggcat cgcaaggcac tgcaattatc tcggagacct gctgctagca 240  
ctttcgttca gcttgccctg tggagtgaat tccgtgggtc catacttcta cccacgtac 300  
ctgctcattc tactggtcct gagggaaagg cgcatgagg cgaggtgctc gcagaagtac 360  
agggagatct gggcagagta ctgcaagctc gtgccgtgga ggatcctgcc ttatgtgtac 420  
tgaagagacg gtagaaacca aggcagctca tggccctggg ccagctgtaa acctatattt 480  
gtttgccctt aaccagttgg tgaatgttga tgtagcactc ggtaaactgt gaccgtgcaa 540  
acttttggtt ttgttggtcc atacatgttt ggaatcgtga atcagaccgc ctcacttggt 600  
ggcaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 660  
aaaaaag 667

<210> 6  
<211> 140  
<212> PRT  
<213> Zea mays

<400> 6  
Pro Arg Val Arg Lys Asn Lys Val Glu Leu Ser Leu Leu Ser Gly Leu  
1 5 10 15  
Ala Asn Leu Cys Ile Phe Leu Ile Gly Tyr Leu Val Phe Arg Gly Ala  
20 25 30  
Asn Lys Gln Lys His Val Phe Lys Lys Asp Pro Lys Ala Pro Ile Trp  
35 40 45  
Gly Lys Pro Pro Lys Val Val Gly Gly Lys Leu Leu Ala Ser Gly Tyr  
50 55 60  
Trp Gly Ile Ala Arg His Cys Asn Tyr Leu Gly Asp Leu Leu Leu Ala  
65 70 75 80  
Leu Ser Phe Ser Leu Pro Cys Gly Val Ser Ser Val Val Pro Tyr Phe  
85 90 95  
Tyr Pro Thr Tyr Leu Leu Ile Leu Leu Val Leu Arg Glu Arg Arg Asp  
100 105 110  
Glu Ala Arg Cys Ser Gln Lys Tyr Arg Glu Ile Trp Ala Glu Tyr Cys  
115 120 125  
Lys Leu Val Pro Trp Arg Ile Leu Pro Tyr Val Tyr  
130 135 140

<210> 7  
 <211> 1364  
 <212> DNA  
 <213> Glycine max

<400> 7  
 ttccggcaccga gtaaaacctc aatctttttac tgaaaagtct caacttttgaa ctccactcgaa 60  
 gtgatgatgg agtcacacgt ggatctaggt tttctccttc aagctctcac tccatcttgg 120  
 aactccgttc ctttgcttgt ggggttcttc acttaacttg cgttgctgg atccattctc 180  
 cctggaaaac ttgttctctg cgttgcaacta ctccgatggaa ctccgtctaca ctattgctgc 240  
 aatggtctgc tctcgcttct tctgttggtt gcacttctcg ggatcgggtgc caagatgggt 300  
 tttgtgtctc ccactgccat atcagacaga ggacttgagc tgctgtccac aacttttgcc 360  
 ttcagttttc ttgtaaccct gatattgcat tttcccggtt gcaagtcaca aagtaaagggt 420  
 tcatcactaa agcctcatct cagtggaaac ctgatacacg attggtggtt tggatatacaa 480  
 ctaaatccac agttcatggg tatcgacctc aaagctggaa tgatgggatg gctacttattc 540  
 aatttatcta ttcttatgaa gagcattcaa gatggtactt tgagccagtc aatgattctc 600  
 taccagctat tctgtgcact atacatcctg gactattttg tacatgaaga gtacatgaca 660  
 tccacctggg acataattgc agagagactg ggcttcatgt tggctcttgg agatttagtg 720  
 tggattcctt tctctttcag catacagga tggtggctct tgatgaacag tgtggagtta 780  
 acaccagctg ccattgtagc taattgcttt gtgttcctga ttggatacat ggtatttcga 840  
 ggagcaaaac agcaaaagca tgtgttcaaa aagaatccaa aggcctctat ctggggtaag 900  
 cctccaaaag tcattggtgg aaagctactt gcttctgggt attggggtat tgctagacac 960  
 tgtaattacc taggggattt gatgcttgc tctccttta gcttaccatg tgggataagt 1020  
 tcaccaattc catacttcta tccaatttat cttcttattc tgtaaatctg gagagagaga 1080  
 acggatgaag ctcgttgcgc cgagaagtat agagagatat gggccgagta tcgtaaaactt 1140  
 gttccatgga gaattattgcc ttacgtttat taggatgaaa aaaaaaagggt cttcaccatg 1200  
 aattcttcat cttgccgatg ttattaagca cttcgatgta aattggttct tgttcttctg 1260  
 gtttcaatct tggatctttt cttattgagc catgtagctg caggagagtg tttcgaggga 1320  
 tttatcttac catctatatt tgtgtaaaaa aaaaaaaaaa aaaa 1364

<210> 8  
 <211> 369  
 <212> PRT  
 <213> Glycine max

<400> 8  
 Met Met Glu Ser His Val Asp Leu Gly Phe Leu Leu Gln Ala Leu Thr  
 1 5 10 15  
 Pro Ser Trp Asn Ser Val Pro Leu Leu Val Gly Phe Phe Thr Tyr Leu  
 20 25 30  
 Ala Val Ala Gly Ser Ile Leu Pro Gly Lys Leu Val Pro Gly Val Ala  
 35 40 45  
 Leu Leu Asp Gly Thr Arg Leu His Tyr Cys Cys Asn Gly Leu Leu Ser  
 50 55 60  
 Leu Leu Leu Leu Val Ala Leu Leu Gly Ile Gly Ala Lys Met Gly Phe  
 65 70 75 80  
 Val Ser Pro Thr Ala Ile Ser Asp Arg Gly Leu Glu Leu Leu Ser Thr  
 85 90 95  
 Thr Phe Ala Phe Ser Phe Leu Val Thr Leu Ile Leu His Phe Ser Gly  
 100 105 110  
 Cys Lys Ser Gln Ser Lys Gly Ser Ser Leu Lys Pro His Leu Ser Gly



Asn Leu Ile His Asp Trp Trp Phe Gly Ile Gln Leu Asn Pro Gln Phe  
130 135 140

Met Gly Ile Asp Leu Lys Ala Gly Met Met Gly Trp Leu Leu Ile Asn  
145 150 155 160

Leu Ser Ile Leu Met Lys Ser Ile Gln Asp Gly Thr Leu Ser Gln Ser  
165 170 175

Met Ile Leu Tyr Gln Leu Phe Cys Ala Leu Tyr Ile Leu Asp Tyr Phe  
180 185 190

Val His Glu Glu Tyr Met Thr Ser Thr Trp Asp Ile Ile Ala Glu Arg  
195 200 205

Leu Gly Phe Met Leu Val Phe Gly Asp Leu Val Trp Ile Pro Phe Ser  
210 215 220

Phe Ser Ile Gln Gly Trp Trp Leu Leu Met Asn Ser Val Glu Leu Thr  
225 230 235 240

Pro Ala Ala Ile Val Ala Asn Cys Phe Val Phe Leu Ile Gly Tyr Met  
245 250 255

Val Phe Arg Gly Ala Asn Lys Gln Lys His Val Phe Lys Lys Asn Pro  
260 265 270

Lys Ala Pro Ile Trp Gly Lys Pro Pro Lys Val Ile Gly Gly Lys Leu  
275 280 285

Leu Ala Ser Gly Tyr Trp Gly Ile Ala Arg His Cys Asn Tyr Leu Gly  
290 295 300

Asp Leu Met Leu Ala Leu Ser Phe Ser Leu Pro Cys Gly Ile Ser Ser  
305 310 315 320

Pro Ile Pro Tyr Phe Tyr Pro Ile Tyr Leu Leu Ile Leu Leu Ile Trp  
325 330 335

Arg Glu Arg Thr Asp Glu Ala Arg Cys Ala Glu Lys Tyr Arg Glu Ile  
340 345 350

Trp Ala Glu Tyr Arg Lys Leu Val Pro Trp Arg Ile Leu Pro Tyr Val  
355 360 365

Tyr  
369

<210> 9  
<211> 430  
<212> PRT  
<213> Ascobolus immersus

<400> 9  
Met Gly Gly Lys Asp Tyr Glu Phe Gly Gly Pro Ile Gly Thr Gly Val  
1 5 10 15

Leu Met Leu Ile Leu Pro Pro Ile Ser His Tyr Leu His Phe Leu Ile

20					25					30					
Thr	Pro	Arg	Gly	Ala	Pro	Pro	Pro	Glu	Phe	Trp	Ser	Ala	Pro	Leu	Glu
		35					40					45			
Thr	Leu	Lys	Ser	Val	Thr	Pro	Thr	Phe	Ser	Ser	Leu	Phe	Ser	Leu	His
	50					55					60				
Ala	Thr	Leu	Ala	Val	Ala	Ala	Tyr	Tyr	Leu	Leu	Leu	Val	Ala	Leu	Met
65						70					75				80
Tyr	Val	Leu	Pro	Ala	Glu	Ile	Ala	Glu	Gly	Val	Val	Leu	Lys	Asp	Gly
				85					90					95	
Ser	Arg	Leu	Lys	Tyr	Arg	Cys	Asn	Ala	Phe	Thr	Thr	Phe	Leu	Val	Phe
			100					105					110		
Phe	Thr	Phe	Leu	Gly	Thr	Met	Thr	Val	Leu	Glu	Gly	Pro	Thr	Trp	Trp
		115					120					125			
Phe	Trp	Ser	Tyr	Leu	Thr	Asp	Asn	Phe	Ala	Gln	Leu	Gln	Ser	Ala	Ser
	130					135					140				
Ile	Val	Phe	Ser	Tyr	Ala	Met	Ser	Leu	Trp	Val	Tyr	Ile	Arg	Ser	Tyr
145						150					155				160
Arg	Pro	Met	Pro	Lys	Gly	Lys	Glu	Val	Ile	Leu	Ser	Pro	Val	Gly	Phe
				165					170					175	
Lys	Gly	Asn	His	Ile	His	Asp	Phe	Trp	Met	Gly	Arg	Glu	Leu	Asn	Pro
			180					185					190		
Arg	Ile	Gly	Glu	Trp	Leu	Asp	Ile	Lys	Gln	Leu	His	Glu	Leu	Arg	Pro
		195					200					205			
Gly	Leu	Met	Gly	Trp	Ile	Leu	Phe	Asn	Leu	Ala	Trp	Thr	Val	Lys	Gln
	210					215					220				
Tyr	Asn	Thr	His	Gly	Phe	Val	Ser	Asp	Ser	Ile	Val	Leu	Val	Asn	Leu
225						230					235				240
Phe	Glu	Thr	Trp	Tyr	Val	Val	Asp	Ala	Leu	Trp	Asn	Glu	Ser	Lys	Val
				245					250					255	
Leu	Thr	Thr	Met	Asp	Ile	Thr	Thr	Asp	Gly	Leu	Gly	Val	Met	Leu	Leu
			260					265					270		
Phe	Gly	Asn	Ala	Val	Trp	Val	Pro	Phe	Met	Tyr	Cys	Leu	Gln	Ala	Arg
		275					280					285			
Tyr	Leu	Ala	Ser	Phe	Pro	Val	His	Leu	Gly	Leu	Leu	Gly	Ile	Ala	Gly
	290					295					300				
Val	Leu	Ala	Val	Gln	Phe	Thr	Gly	Tyr	Ala	Ile	Phe	Arg	Gly	Ala	Asn
305						310					315				320
Asn	Gln	Lys	Asn	Ala	Phe	Arg	Thr	Asn	Pro	Ala	Asp	Pro	Ala	Val	Ser
				325					330					335	
His	Leu	Lys	Phe	Met	Thr	Thr	Lys	Ser	Gly	Ser	Lys	Leu	Leu	Ile	Ser

Gly Trp Trp Gly Val Ala Arg His Val Asn Tyr Phe Gly Asp Trp Ile  
 355 360 365  
 Met Ala Trp Ser Tyr Cys Leu Thr Thr Gly Phe Asn Thr Pro Leu Thr  
 370 375 380  
 Tyr Phe Tyr Val Ile Tyr Phe Gly Ile Leu Leu Leu His Arg Asp Arg  
 385 390 395 400  
 Arg Asp Glu Ala Lys Cys Arg Glu Lys Tyr Gly Lys Asp Trp Asp Arg  
 405 410 415  
 Tyr Cys Lys Val Val Lys Trp Arg Ile Ile Pro Gly Ile Tyr  
 420 425 430

<210> 10  
 <211> 365  
 <212> PRT  
 <213> Arabidopsis thaliana

<400> 10  
 Met Asp Leu Gly Val Leu Leu Pro Ser Leu Gln Ser Val Tyr Val Leu  
 1 5 10 15  
 Val Phe Tyr Phe Val Tyr Leu Ala Val Ala Gly Glu Ile Leu Pro Gly  
 20 25 30  
 Lys Val Ile Arg Gly Val Leu Leu Ser Asp Gly Ser Gln Leu Arg Tyr  
 35 40 45  
 Arg Cys Asn Gly Leu Leu Ala Leu Ile Leu Leu Val Ala Ile Leu Gly  
 50 55 60  
 Ile Cys Ala Lys Leu Gly Ile Val Ser Pro Leu Val Val Ala Asp Arg  
 65 70 75 80  
 Gly Leu Glu Leu Leu Ser Ala Thr Phe Ile Phe Cys Val Leu Val Thr  
 85 90 95  
 Leu Ala Leu Tyr Val Thr Gly Arg Ser Ser Ser Asn Lys Gly Ser Ser  
 100 105 110  
 Leu Lys Pro His Val Ser Gly Asn Leu Val His Asp Trp Trp Phe Gly  
 115 120 125  
 Ile Gln Leu Asn Pro Gln Phe Met Ser Ile Asp Leu Lys Phe Phe Phe  
 130 135 140  
 Val Arg Ala Gly Met Met Gly Trp Leu Leu Ile Asn Leu Ser Ile Leu  
 145 150 155 160  
 Ala Lys Ser Val Gln Asp Gly Ser Leu Ser Gln Ser Met Ile Leu Tyr  
 165 170 175  
 Gln Ile Phe Cys Ala Leu Tyr Ile Leu Asp Tyr Phe Val His Glu Glu  
 180 185 190

Tyr Met Thr Ser Thr Trp Asp Ile Ile Ala Glu Arg Leu Gly Phe Met  
 195 200 205

Leu Val Phe Gly Asp Leu Leu Trp Ile Pro Phe Thr Phe Ser Ile Gln  
 210 215 220

Gly Trp Trp Leu Leu His Asn Lys Val Glu Leu Thr Val Pro Ala Ile  
 225 230 235 240

Val Val Asn Cys Leu Val Phe Leu Ile Gly Tyr Met Val Phe Arg Gly  
 245 250 255

Ala Asn Lys Gln Lys His Ile Phe Lys Lys Asn Pro Lys Thr Pro Ile  
 260 265 270

Trp Gly Lys Pro Pro Val Val Val Gly Gly Lys Leu Leu Val Ser Gly  
 275 280 285

Tyr Trp Gly Ile Ala Arg His Cys Asn Tyr Leu Gly Asp Leu Met Leu  
 290 295 300

Ala Leu Ser Phe Ser Leu Pro Cys Gly Ile Ser Ser Pro Val Pro Tyr  
 305 310 315 320

Phe Tyr Pro Ile Tyr Leu Leu Ile Leu Leu Ile Trp Arg Glu Arg Arg  
 325 330 335

Asp Glu Val Arg Cys Ala Glu Lys Tyr Lys Glu Ile Trp Ala Glu Tyr  
 340 345 350

Leu Arg Leu Val Pro Trp Arg Ile Leu Pro Tyr Val Tyr  
 355 360 365

525 HOD PCT/PTO 16 JUL 2002

PTO/SB/92 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

NIN  
soef

## Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner For Patents, Box PCT  
Washington, D.C. 20231

on July 11, 2002  
Date

Susan L. Durkee  
Signature

SUSAN L. DURKEE  
Type or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

10/069,427  
BB1395 US PCT  
STATEMENT UNDER 37 CFR 1.821 (g) and 1.825(b)  
SEQ. DISKETTE - CRF  
SEQUENCE LISTING - PAPER COPY 9 PAGES  
FEE SHEET  
PETITION FOR ONE MONTH EXTENSION OF TIME  
COPY OF NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 USC 371  
POSTCARD

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<b>PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)</b>		Docket Number (Optional) BB1395 US PCT
In re Application of OMOLAYO O. FAMODU ET AL.		
Application Number 10/069,427		Filed UNKNOWN
For GENES ENCODING STEROL DELTA-15 REDUCTASE IN PLANTS		
Group Art Unit UNKNOWN	Examiner UNKNOWN	

This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a reply in the above identified application.

The requested extension and appropriate non-small-entity fee are as follows (check time period desired):

<input checked="" type="checkbox"/> One month (37 CFR 1.17(a)(1))	\$110.00
<input type="checkbox"/> Two months (37 CFR 1.17(a)(2))	\$
<input type="checkbox"/> Three months (37 CFR 1.17(a)(3))	\$
<input type="checkbox"/> Four months (37 CFR 1.17(a)(4))	\$
<input type="checkbox"/> Five months (37 CFR 1.17(a)(5))	\$

☐ Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$ \_\_\_\_\_.

☐ A check in the amount of the fee is enclosed.

☐ Payment by credit card. Form PTO-2038 is attached.

☐ The Commissioner has already been authorized to charge fees in this application to a Deposit Account.

☒ The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 04-1928.

I have enclosed a duplicate copy of this sheet.

I am the ☐ applicant/inventor.

☐ assignee of record of the entire interest. See 37 CFR 3.71

Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).

☒ attorney or agent of record.

☐ attorney or agent under 37 CFR 1.34(a).

Registration number if acting under 37 CFR 1.34(a). \_\_\_\_\_.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

July 11, 2002

Date

Lori Y. Beardsell

Signature

07/22/2002 SNAJARRO 00000048 041928 10069427

0 FC:115 110.00 CH

LORI Y. BEARDELL

Typed or printed name

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below\*.

☒ \*Total of 1 forms are submitted.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h2 style="margin: 0;">FEE TRANSMITTAL for FY 2002</h2> <p style="margin: 5px 0 0 40px;"><i>Patent fees are subject to annual revision</i></p>		<p><b>Complete If Known</b></p>	
<input type="checkbox"/> Applicant Claims small entity status. See 37 CFR 1.27		Application Number	10/069,427
<p><b>TOTAL AMOUNT OF PAYMENT</b> (\$ ) 110</p>		Filing Date	UNKNOWN
		First Named Inventor	OMOLAYO O. FAMODU ET AL.
		Examiner Name	UNKNOWN
		Group / Art Unit	UNKNOWN
		Attorney Docket No.	BB1395 US PCT

<p><b>METHOD OF PAYMENT (check all that apply)</b></p> <p> <input type="checkbox"/> Check                    <input type="checkbox"/> Credit card                    <input type="checkbox"/> Money Order                    <input type="checkbox"/> Other                    <input type="checkbox"/> None             </p> <p><input checked="" type="checkbox"/> Deposit Account:</p> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">                 Deposit Account Number: <b>04-1928</b> </div> <div style="border: 1px solid black; padding: 5px; margin-top: 5px;">                 Deposit Account Name: <b>E. I. du Pont de Nemours and Company</b> </div> <p><b>The Commissioner is authorized to: (check all that apply)</b></p> <p> <input checked="" type="checkbox"/> Charge fee(s) indicated below                    <input checked="" type="checkbox"/> Credit any overpayments  <input checked="" type="checkbox"/> Charge any additional fee(s) during the pendency of this application  <input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account             </p> <p style="text-align: center;"><b>FEE CALCULATION</b></p> <p><b>1. BASIC FILING FEE</b></p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2">Large Entity</th> <th colspan="2">Small Entity</th> <th rowspan="2">Fee Description</th> <th rowspan="2">Fee Paid</th> </tr> <tr> <th>Fee Code</th> <th>Fee (\$)</th> <th>Fee Code</th> <th>Fee (\$)</th> </tr> </thead> <tbody> <tr> <td>101</td> <td>740</td> <td>201</td> <td>370</td> <td>Utility filing fee</td> <td></td> </tr> <tr> <td>106</td> <td>330</td> <td>206</td> <td>165</td> <td>Design filing fee</td> <td></td> </tr> <tr> <td>107</td> <td>510</td> <td>207</td> <td>255</td> <td>Plant filing fee</td> <td></td> </tr> <tr> <td>108</td> <td>740</td> <td>208</td> <td>370</td> <td>Reissue filing fee</td> <td></td> </tr> <tr> <td>114</td> <td>160</td> <td>214</td> <td>80</td> <td>Provisional filing fee</td> <td></td> </tr> <tr> <td colspan="5" style="text-align: right;"><b>SUBTOTAL (1)</b></td> <td>(\$ ) 0</td> </tr> </tbody> </table> <p><b>2. EXTRA CLAIM FEES</b></p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td>Total Claims</td> <td></td> <td>-20</td> <td>=</td> <td>0</td> <td>X</td> <td>18</td> <td>=</td> <td>0</td> </tr> <tr> <td>Independent Claims</td> <td></td> <td>-3</td> <td>=</td> <td>0</td> <td>X</td> <td>84</td> <td>=</td> <td>0</td> </tr> <tr> <td>Multiple Dependent</td> <td><input type="checkbox"/></td> <td></td> <td></td> <td></td> <td>X</td> <td>280</td> <td>=</td> <td>0</td> </tr> </table> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2">Large Entity</th> <th colspan="2">Small Entity</th> <th rowspan="2">Fee Description</th> <th rowspan="2">Fee Paid</th> </tr> <tr> <th>Fee Code</th> <th>Fee (\$)</th> <th>Fee Code</th> <th>Fee (\$)</th> </tr> </thead> <tbody> <tr> <td>103</td> <td>18</td> <td>203</td> <td>9</td> <td>Claims in excess of 20</td> <td></td> </tr> <tr> <td>102</td> <td>84</td> <td>202</td> <td>42</td> <td>Independent claims in excess of 3</td> <td></td> </tr> <tr> <td>104</td> <td>280</td> <td>204</td> <td>140</td> <td>Multiple dependent claim, if not paid</td> <td></td> </tr> <tr> <td>109</td> <td>84</td> <td>209</td> <td>42</td> <td>** Reissue independent claims over original patent</td> <td></td> </tr> <tr> <td>110</td> <td>18</td> <td>210</td> <td>9</td> <td>** Reissue claims in excess of 20 and over original patent</td> <td></td> </tr> <tr> <td colspan="5" style="text-align: right;"><b>SUBTOTAL (2)</b></td> <td>(\$ ) 0</td> </tr> </tbody> </table> <p><small>**or number previously paid, if greater; For Reissues, see above</small></p>	Large Entity		Small Entity		Fee Description	Fee Paid	Fee Code	Fee (\$)	Fee Code	Fee (\$)	101	740	201	370	Utility filing fee		106	330	206	165	Design filing fee		107	510	207	255	Plant filing fee		108	740	208	370	Reissue filing fee		114	160	214	80	Provisional filing fee		<b>SUBTOTAL (1)</b>					(\$ ) 0	Total Claims		-20	=	0	X	18	=	0	Independent Claims		-3	=	0	X	84	=	0	Multiple Dependent	<input type="checkbox"/>				X	280	=	0	Large Entity		Small Entity		Fee Description	Fee Paid	Fee Code	Fee (\$)	Fee Code	Fee (\$)	103	18	203	9	Claims in excess of 20		102	84	202	42	Independent claims in excess of 3		104	280	204	140	Multiple dependent claim, if not paid		109	84	209	42	** Reissue independent claims over original patent		110	18	210	9	** Reissue claims in excess of 20 and over original patent		<b>SUBTOTAL (2)</b>					(\$ ) 0	<p style="text-align: center;"><b>FEE CALCULATION (continued)</b></p> <p><b>3. ADDITIONAL FEES</b></p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th colspan="2">Large Entity</th> <th colspan="2">Small Entity</th> <th rowspan="2">Fee Description</th> <th rowspan="2">Fee Paid</th> </tr> <tr> <th>Fee Code</th> <th>Fee (\$)</th> <th>Fee Code</th> <th>Fee (\$)</th> </tr> </thead> <tbody> <tr> <td>127</td> <td>50</td> <td>227</td> <td>25</td> <td>Surcharge - late filing fee or oath</td> <td></td> </tr> <tr> <td>139</td> <td>130</td> <td>139</td> <td>130</td> <td>Non-English specification</td> <td></td> </tr> <tr> <td>147</td> <td>2,520</td> <td>147</td> <td>2,520</td> <td>For filing a request for reexamination</td> <td></td> </tr> <tr> <td>112</td> <td>920*</td> <td>112</td> <td>920*</td> <td>Requesting publication of SIR prior to Examiner action</td> <td></td> </tr> <tr> <td>113</td> <td>1,840*</td> <td>113</td> <td>1,840*</td> <td>Requesting publication of SIR after Examiner action</td> <td></td> </tr> <tr> <td>115</td> <td>110</td> <td>215</td> <td>55</td> <td>Extension for reply within first month</td> <td>110</td> </tr> <tr> <td>116</td> <td>400</td> <td>216</td> <td>200</td> <td>Extension for reply within second month</td> <td></td> </tr> <tr> <td>117</td> <td>920</td> <td>217</td> <td>460</td> <td>Extension for reply within third month</td> <td></td> </tr> <tr> <td>118</td> <td>1,440</td> <td>218</td> <td>720</td> <td>Extension for reply within fourth month</td> <td></td> </tr> <tr> <td>128</td> <td>1,960</td> <td>228</td> <td>980</td> <td>Extension for reply within fifth month</td> <td></td> </tr> <tr> <td>119</td> <td>320</td> <td>219</td> <td>160</td> <td>Notice of Appeal</td> <td></td> </tr> <tr> <td>120</td> <td>320</td> <td>220</td> <td>160</td> <td>Filing a brief in support of an appeal</td> <td></td> </tr> <tr> <td>121</td> <td>280</td> <td>221</td> <td>140</td> <td>Request for oral hearing</td> <td></td> </tr> <tr> <td>138</td> <td>1,510</td> <td>138</td> <td>1,510</td> <td>Petition to institute a public use proceeding</td> <td></td> </tr> <tr> <td>140</td> <td>110</td> <td>240</td> <td>55</td> <td>Petition to revive - unavoidable</td> <td></td> </tr> <tr> <td>141</td> <td>1,280</td> <td>241</td> <td>640</td> <td>Petition to revive - unintentional</td> <td></td> </tr> <tr> <td>142</td> <td>1,280</td> <td>242</td> <td>640</td> <td>Utility issue fee (or reissue)</td> <td></td> </tr> <tr> <td>143</td> <td>460</td> <td>243</td> <td>230</td> <td>Design issue fee</td> <td></td> </tr> <tr> <td>144</td> <td>620</td> <td>244</td> <td>310</td> <td>Plant issue fee</td> <td></td> </tr> <tr> <td>122</td> <td>130</td> <td>122</td> <td>130</td> <td>Petitions to the Commissioner</td> <td></td> </tr> <tr> <td>123</td> <td>50</td> <td>123</td> <td>50</td> <td>Processing fee under 37 CFR 1.17(q)</td> <td></td> </tr> <tr> <td>126</td> <td>180</td> <td>126</td> <td>180</td> <td>Submission of Information Disclosure Stmt</td> <td></td> </tr> <tr> <td>581</td> <td>40</td> <td>581</td> <td>40</td> <td>Recording each patent assignment per property (times number of properties)</td> <td></td> </tr> <tr> <td>146</td> <td>740</td> <td>246</td> <td>370</td> <td>Filing a submission after final rejection (37 CFR § 1.129(a))</td> <td></td> </tr> <tr> <td>149</td> <td>740</td> <td>249</td> <td>370</td> <td>For each additional invention to be examined (37 CFR § 1.129(b))</td> <td></td> </tr> <tr> <td>179</td> <td>740</td> <td>279</td> <td>370</td> <td>Request for Continued Examination (RCE)</td> <td></td> </tr> <tr> <td>169</td> <td>900</td> <td>169</td> <td>900</td> <td>Request for expedited examination of a design application</td> <td></td> </tr> </tbody> </table> <p>Other fee (specify) _____</p> <p><b>*Reduced by Basic Filing Fee Paid</b>      <b>SUBTOTAL (3)</b> (\$ ) 110</p>	Large Entity		Small Entity		Fee Description	Fee Paid	Fee Code	Fee (\$)	Fee Code	Fee (\$)	127	50	227	25	Surcharge - late filing fee or oath		139	130	139	130	Non-English specification		147	2,520	147	2,520	For filing a request for reexamination		112	920*	112	920*	Requesting publication of SIR prior to Examiner action		113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action		115	110	215	55	Extension for reply within first month	110	116	400	216	200	Extension for reply within second month		117	920	217	460	Extension for reply within third month		118	1,440	218	720	Extension for reply within fourth month		128	1,960	228	980	Extension for reply within fifth month		119	320	219	160	Notice of Appeal		120	320	220	160	Filing a brief in support of an appeal		121	280	221	140	Request for oral hearing		138	1,510	138	1,510	Petition to institute a public use proceeding		140	110	240	55	Petition to revive - unavoidable		141	1,280	241	640	Petition to revive - unintentional		142	1,280	242	640	Utility issue fee (or reissue)		143	460	243	230	Design issue fee		144	620	244	310	Plant issue fee		122	130	122	130	Petitions to the Commissioner		123	50	123	50	Processing fee under 37 CFR 1.17(q)		126	180	126	180	Submission of Information Disclosure Stmt		581	40	581	40	Recording each patent assignment per property (times number of properties)		146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))		149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))		179	740	279	370	Request for Continued Examination (RCE)		169	900	169	900	Request for expedited examination of a design application	
Large Entity		Small Entity		Fee Description			Fee Paid																																																																																																																																																																																																																																																																																													
Fee Code	Fee (\$)	Fee Code	Fee (\$)																																																																																																																																																																																																																																																																																																	
101	740	201	370	Utility filing fee																																																																																																																																																																																																																																																																																																
106	330	206	165	Design filing fee																																																																																																																																																																																																																																																																																																
107	510	207	255	Plant filing fee																																																																																																																																																																																																																																																																																																
108	740	208	370	Reissue filing fee																																																																																																																																																																																																																																																																																																
114	160	214	80	Provisional filing fee																																																																																																																																																																																																																																																																																																
<b>SUBTOTAL (1)</b>					(\$ ) 0																																																																																																																																																																																																																																																																																															
Total Claims		-20	=	0	X	18	=	0																																																																																																																																																																																																																																																																																												
Independent Claims		-3	=	0	X	84	=	0																																																																																																																																																																																																																																																																																												
Multiple Dependent	<input type="checkbox"/>				X	280	=	0																																																																																																																																																																																																																																																																																												
Large Entity		Small Entity		Fee Description	Fee Paid																																																																																																																																																																																																																																																																																															
Fee Code	Fee (\$)	Fee Code	Fee (\$)																																																																																																																																																																																																																																																																																																	
103	18	203	9	Claims in excess of 20																																																																																																																																																																																																																																																																																																
102	84	202	42	Independent claims in excess of 3																																																																																																																																																																																																																																																																																																
104	280	204	140	Multiple dependent claim, if not paid																																																																																																																																																																																																																																																																																																
109	84	209	42	** Reissue independent claims over original patent																																																																																																																																																																																																																																																																																																
110	18	210	9	** Reissue claims in excess of 20 and over original patent																																																																																																																																																																																																																																																																																																
<b>SUBTOTAL (2)</b>					(\$ ) 0																																																																																																																																																																																																																																																																																															
Large Entity		Small Entity		Fee Description	Fee Paid																																																																																																																																																																																																																																																																																															
Fee Code	Fee (\$)	Fee Code	Fee (\$)																																																																																																																																																																																																																																																																																																	
127	50	227	25	Surcharge - late filing fee or oath																																																																																																																																																																																																																																																																																																
139	130	139	130	Non-English specification																																																																																																																																																																																																																																																																																																
147	2,520	147	2,520	For filing a request for reexamination																																																																																																																																																																																																																																																																																																
112	920*	112	920*	Requesting publication of SIR prior to Examiner action																																																																																																																																																																																																																																																																																																
113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action																																																																																																																																																																																																																																																																																																
115	110	215	55	Extension for reply within first month	110																																																																																																																																																																																																																																																																																															
116	400	216	200	Extension for reply within second month																																																																																																																																																																																																																																																																																																
117	920	217	460	Extension for reply within third month																																																																																																																																																																																																																																																																																																
118	1,440	218	720	Extension for reply within fourth month																																																																																																																																																																																																																																																																																																
128	1,960	228	980	Extension for reply within fifth month																																																																																																																																																																																																																																																																																																
119	320	219	160	Notice of Appeal																																																																																																																																																																																																																																																																																																
120	320	220	160	Filing a brief in support of an appeal																																																																																																																																																																																																																																																																																																
121	280	221	140	Request for oral hearing																																																																																																																																																																																																																																																																																																
138	1,510	138	1,510	Petition to institute a public use proceeding																																																																																																																																																																																																																																																																																																
140	110	240	55	Petition to revive - unavoidable																																																																																																																																																																																																																																																																																																
141	1,280	241	640	Petition to revive - unintentional																																																																																																																																																																																																																																																																																																
142	1,280	242	640	Utility issue fee (or reissue)																																																																																																																																																																																																																																																																																																
143	460	243	230	Design issue fee																																																																																																																																																																																																																																																																																																
144	620	244	310	Plant issue fee																																																																																																																																																																																																																																																																																																
122	130	122	130	Petitions to the Commissioner																																																																																																																																																																																																																																																																																																
123	50	123	50	Processing fee under 37 CFR 1.17(q)																																																																																																																																																																																																																																																																																																
126	180	126	180	Submission of Information Disclosure Stmt																																																																																																																																																																																																																																																																																																
581	40	581	40	Recording each patent assignment per property (times number of properties)																																																																																																																																																																																																																																																																																																
146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))																																																																																																																																																																																																																																																																																																
149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))																																																																																																																																																																																																																																																																																																
179	740	279	370	Request for Continued Examination (RCE)																																																																																																																																																																																																																																																																																																
169	900	169	900	Request for expedited examination of a design application																																																																																																																																																																																																																																																																																																

<b>SUBMITTED BY</b>		<b>Complete (if applicable)</b>	
Name (Print/Type)	LORI Y BEARDELL	Registration No. Attorney/Agent)	34,293
Signature		Telephone	302-992-4926
		Date	July 11, 2002

**WARNING:** Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

**Burden Hour Statement:** This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

TITLEGENES ENCODING STEROL DELTA-15 REDUCTASE IN PLANTS

This application claims the benefit of U.S. Provisional Application No. 60/156820, filed September 30, 1999.

FIELD OF THE INVENTION

This invention is in the field of plant molecular biology. More specifically, this invention pertains to nucleic acid fragments encoding sterol delta-14 reductase in plants and seeds.

BACKGROUND OF THE INVENTION

Sterols are cyclic hydrocarbon molecules that help regulate the fluidity of cellular membranes. Sterols are essential components in all eukaryotic cells, and inhibitors that completely block sterol synthesis will block cell division and generally lead to cell death. In humans the predominant membrane sterol is cholesterol, which serves its structural role in membranes, and also serves as the precursor to hormones, bile salts, and modified membrane components. In fungi, the predominant sterol is often ergosterol, which follows the same biosynthetic pathway as cholesterol but contains an additional methyl group and altered double-bond placements. In plants there are multiple sterols working in different combinations, with stigmasterol and sitosterol as the most common components. The plant sterols tend to have 29 carbons, versus the 28 carbons of ergosterol, and the 27 carbons of cholesterol, but all are synthesized from the common precursors squalene and lanosterol.

The biosynthetic pathway leading to the final sterol products is long and complicated, requiring significant amounts of cellular energy to drive the multiple NADH (and/or NADPH) driven reduction steps. One enzyme in this pathway, sterol delta-14 reductase has been extensively studied in fungi because of its involvement in ergosterol synthesis (Lai et al. (1994) *Gene* 140: 41-49; Parks et al. (1995) *Lipids* 30: 227-230). Mutants in sterol delta-14 reductase accumulate the aberrant sterol ignosterol, and can be supplemented with nutrients and growth conditions to survive (Palermo et al. (1997) *Curr Genet* 32: 93-99; Crowley et al. (1996) *J Bacteriol* 178: 2991-2993). The gene encoding this enzyme has been cloned and studied as a target for fungicidal agents (Marcireau et al. (1992) *Curr Genet* 22: 267-272; Barrett-Bee and Dixon (1995) *Acta Biochim Pol* 42: 465-479).

Prior to the instant invention, no plant sterol delta-14 reductase genes have been isolated. Availability of such plant genes will enable one to alter sterol production and/or composition in plants, to identify compounds that may be used as novel herbicides and fungicides, and to identify mutants of these genes that are resistant to these herbicides that will enable the production of herbicide-resistant crops.



### SUMMARY OF THE INVENTION

The present invention is directed to an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) a first nucleotide sequence encoding a polypeptide of at least 126 amino acids having at least 50% identity based on the Clustal method of alignment when compared to a polypeptide consisting of SEQ ID NO:2, or preferably 369 amino acids having at least 82% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:4, 6, and 8, or (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

In a second embodiment, it is preferred that the isolated polynucleotide of the claimed invention comprises a first nucleotide sequence which comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, and 8.

In a third embodiment, this invention concerns an isolated polynucleotide comprising a nucleotide sequence of at least one of 300 (preferably at least one of 200, most preferably at least one of 125) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7 and the complement of such nucleotide sequences.

In a fourth embodiment, this invention relates to a chimeric gene comprising an isolated polynucleotide of the present invention operably linked to at least one suitable regulatory sequence.

In a fifth embodiment, the present invention concerns an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention. The host cell may be eukaryotic, such as a yeast or a plant cell, or prokaryotic, such as a bacterial cell. The present invention also relates to a virus, preferably a baculovirus, comprising an isolated polynucleotide of the present invention or a chimeric gene of the present invention.

In a sixth embodiment, the invention also relates to a process for producing an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention, the process comprising either transforming or transfecting an isolated compatible host cell with a chimeric gene or isolated polynucleotide of the present invention.

In a seventh embodiment, the invention concerns a plant sterol delta-14 reductase polypeptide of at least 126 amino acids comprising at least 50% identity based on the Clustal method of alignment when compared to a polypeptide consisting of SEQ ID NO:2, or preferably 369 amino acids comprising at least 82% identity based on the Clustal method of

alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:4, 6, and 8,.

In an eighth embodiment, the invention relates to a method of selecting an isolated polynucleotide that affects the level of expression of a plant sterol delta-14 reductase polypeptide or enzyme activity in a host cell, preferably a plant cell, the method comprising the steps of: (a) constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; (b) introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; (c) measuring the level of the plant sterol delta-14 reductase polypeptide or enzyme activity in the host cell containing the isolated polynucleotide; and (d) comparing the level of the plant sterol delta-14 reductase polypeptide or enzyme activity in the host cell containing the isolated polynucleotide with the level of the plant sterol delta-14 reductase polypeptide or enzyme activity in the host cell that does not contain the isolated polynucleotide.

In a ninth embodiment, the invention concerns a method of obtaining a nucleic acid fragment encoding a substantial portion of a plant sterol delta-14 reductase polypeptide, preferably a plant plant sterol delta-14 reductase polypeptide, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7, and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a substantial portion of a plant sterol delta-14 reductase amino acid sequence.

In a tenth embodiment, this invention relates to a method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding a plant sterol delta-14 reductase polypeptide comprising the steps of: probing a cDNA or genomic library with an isolated polynucleotide of the present invention; identifying a DNA clone that hybridizes with an isolated polynucleotide of the present invention; isolating the identified DNA clone; and sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

In an eleventh embodiment, this invention concerns a composition, such as a hybridization mixture, comprising an isolated polynucleotide of the present invention.

In a twelfth embodiment, this invention concerns a method for positive selection of a transformed cell comprising: (a) transforming a host cell with the chimeric gene of the present invention or an expression cassette of the present invention; and (b) growing the transformed host cell, preferably a plant cell, such as a monocot or a dicot, under conditions

which allow expression of the plant sterol delta-14 reductase polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means.

In a thirteenth embodiment, this invention relates to a method of altering the level of expression of a sterol delta-14 reductase in a host cell comprising: (a) transforming a host cell with a chimeric gene of the present invention; and (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in production of altered levels of the sterol delta-14 reductase in the transformed host cell.

A further embodiment of the instant invention is a method for evaluating at least one compound for its ability to inhibit the activity of a sterol delta-14 reductase, the method comprising the steps of: (a) transforming a host cell with a chimeric gene comprising a nucleic acid fragment encoding a sterol delta-14 reductase polypeptide, operably linked to suitable regulatory sequences; (b) growing the transformed host cell under conditions that are suitable for expression of the chimeric gene wherein expression of the chimeric gene results in altered production, and/or ratios, of phytosterols in the transformed host cell; (c) optionally purifying the sterol delta-14 reductase polypeptide expressed by the transformed host cell; (d) treating the sterol delta-14 reductase polypeptide with a compound to be tested; and (e) comparing the activity of the sterol delta-14 reductase polypeptide that has been treated with a test compound to the activity of an untreated sterol delta-14 reductase polypeptide, thereby selecting compounds with potential for inhibitory activity.

#### BRIEF DESCRIPTION OF THE DRAWINGS AND SEQUENCE LISTINGS

The invention can be more fully understood from the following detailed description and the accompanying drawings and Sequence Listing which form a part of this application.

Figure 1 shows a comparison of the amino acid sequences encoded by a corn and two soybean sterol delta-14 reductase cDNAs (SEQ ID NOs:4, 6, and 8, respectively), and the *Arabidopsis thaliana* sequence (SEQ ID NO:10) that is the closest BLAST homolog.

Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

TABLE 1  
Sterol Delta-14 Reductase

Protein	Clone Designation	SEQ ID NO:	
		(Nucleotide)	(Amino Acid)
Soybean sterol delta-14 reductase	src3c.pk009.c1	1	2
Corn sterol delta-14 reductase	p0097.cqrau67ra:fis	3	4
Soybean sterol delta-14 reductase	src3c.pk009.c1:fis	5	6
Soybean sterol delta-14 reductase	ssm.pk0031.d12:fis	7	8

The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB standards described in *Nucleic Acids Res.* 13:3021-3030 (1985) and in the *Biochemical J.* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

#### DETAILED DESCRIPTION OF THE INVENTION

In the context of this disclosure, a number of terms shall be utilized. The terms "polynucleotide", "polynucleotide sequence", "nucleic acid sequence", and "nucleic acid fragment"/"isolated nucleic acid fragment" are used interchangeably herein. These terms encompass nucleotide sequences and the like. A polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof. An isolated polynucleotide of the present invention may include at least one of 300 contiguous nucleotides, preferably 200 contiguous nucleotides, more preferably 125 nucleotides, again more preferably 60 contiguous nucleotides, once again more preferably at least one of 40 contiguous nucleotides, and most preferably one of at least 30 contiguous nucleotides derived from SEQ ID NOs:1, 3, 5, and 7, or the complement of such sequences.

The term "isolated" polynucleotide refers to a polynucleotide that is substantially free from other nucleic acid sequences, such as other chromosomal and extrachromosomal DNA and RNA, that normally accompany or interact with it as found in its naturally occurring environment. Isolated polynucleotides may be purified from a host cell in which they naturally occur. Conventional nucleic acid purification methods known to skilled artisans may be used to obtain isolated polynucleotides. The term also embraces recombinant polynucleotides and chemically synthesized polynucleotides.

The term "recombinant" means, for example, that a nucleic acid sequence is made by an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated nucleic acids by genetic engineering techniques.

As used herein, "contig" refers to a nucleotide sequence that is assembled from two or more constituent nucleotide sequences that share common or overlapping regions of sequence homology. For example, the nucleotide sequences of two or more nucleic acid fragments can be compared and aligned in order to identify common or overlapping sequences. Where common or overlapping sequences exist between two or more nucleic acid fragments, the sequences (and thus their corresponding nucleic acid fragments) can be assembled into a single contiguous nucleotide sequence.

As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate alteration of gene expression by gene silencing through for example antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate gene silencing or alteration of the functional properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and includes functional equivalents thereof. The terms "substantially similar" and "corresponding substantially" are used interchangeably herein.

Substantially similar nucleic acid fragments may be selected by screening nucleic acid fragments representing subfragments or modifications of the nucleic acid fragments of the instant invention, wherein one or more nucleotides are substituted, deleted and/or inserted, for their ability to affect the level of the polypeptide encoded by the unmodified nucleic acid fragment in a plant or plant cell. For example, a substantially similar nucleic acid fragment representing at least one of 30 contiguous nucleotides derived from the instant nucleic acid fragment can be constructed and introduced into a plant or plant cell. The level of the polypeptide encoded by the unmodified nucleic acid fragment present in a plant or plant cell exposed to the substantially similar nucleic fragment can then be compared to the level of the polypeptide in a plant or plant cell that is not exposed to the substantially similar nucleic acid fragment.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than

the entire coding region of a gene, and by using nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Consequently, an isolated polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, and 7, and the complement of such nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of a plant sterol delta-14 reductase polypeptide in a host cell. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a virus or in a host cell (eukaryotic, such as plant or yeast, prokaryotic such as bacterial) may comprise the steps of: constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; measuring the level of a polypeptide or enzyme activity in the host cell containing the isolated polynucleotide; and comparing the level of a polypeptide or enzyme activity in the host cell containing the isolated polynucleotide with the level of a polypeptide or enzyme activity in a host cell that does not contain the isolated polynucleotide.

Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) *Nucleic Acid Hybridisation*, IRL Press, Oxford, U.K.). Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room temperature for 15 min,

then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C.

- 5 Another preferred set of highly stringent conditions uses two final washes in 0.1X SSC, 0.1% SDS at 65°C.

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Suitable nucleic acid fragments (isolated polynucleotides of the present invention) encode polypeptides that are at least about 70% identical, preferably at least about 80% identical to the amino acid sequences reported herein. Preferred nucleic acid fragments encode amino acid sequences that are about 85% identical to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that are at least about 90% identical to the amino acid sequences reported herein. Most preferred are nucleic acid fragments that encode amino acid sequences that are at least about 95% identical to the amino acid sequences reported herein. Suitable nucleic acid fragments not only have the above identities but typically encode a polypeptide having at least 50 amino acids, preferably at least 100 amino acids, more preferably at least 150 amino acids, still more preferably at least 200 amino acids, and most preferably at least 250 amino acids. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

A "substantial portion" of an amino acid or nucleotide sequence comprises an amino acid or a nucleotide sequence that is sufficient to afford putative identification of the protein or gene that the amino acid or nucleotide sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools that employ algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes

comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular  
5 nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of the  
10 sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

"Codon degeneracy" refers to divergence in the genetic code permitting variation of  
15 the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid.  
20 Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell, it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

"Synthetic nucleic acid fragments" can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art.  
25 These building blocks are ligated and annealed to form larger nucleic acid fragments which may then be enzymatically assembled to construct the entire desired nucleic acid fragment. "Chemically synthesized", as related to a nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis  
30 can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal gene expression based on optimization of the nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a  
35 survey of genes derived from the host cell where sequence information is available.

"Gene" refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding



sequences) the coding sequence. "Native gene" refers to a gene as found in nature with its own regulatory sequences. "Chimeric gene" refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature.

Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived

from the same source, but arranged in a manner different than that found in nature. "Endogenous gene" refers to a native gene in its natural location in the genome of an organism. A "foreign-gene" refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A "transgene" is a gene that has been introduced into the genome by a transformation procedure.

"Coding sequence" refers to a nucleotide sequence that codes for a specific amino acid sequence. "Regulatory sequences" refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

"Promoter" refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an "enhancer" is a nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or may be composed of different elements derived from different promoters found in nature, or may even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, nucleic acid fragments of different lengths may have identical promoter activity.

"Translation leader sequence" refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is

present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Mol. Biotechnol.* 3:225-236).

5       “3' non-coding sequences” refer to nucleotide sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is  
10       exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

      “RNA transcript” refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is  
15       referred to as the mature RNA. “Messenger RNA (mRNA)” refers to the RNA that is without introns and that can be translated into polypeptides by the cell. “cDNA” refers to DNA that is complementary to and derived from an mRNA template. The cDNA can be single-stranded or converted to double stranded form using, for example, the Klenow fragment of DNA polymerase I. “Sense-RNA” refers to an RNA transcript that includes the  
20       mRNA and so can be translated into a polypeptide by the cell. “Antisense RNA” refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the expression of a target gene (see U.S. Patent No. 5,107,065, incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-  
25       coding sequence, introns, or the coding sequence. “Functional RNA” refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

      The term “operably linked” refers to the association of two or more nucleic acid fragments on a single polynucleotide so that the function of one is affected by the other. For  
30       example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in sense or antisense orientation.

      The term “expression”, as used herein, refers to the transcription and stable  
35       accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide. “Antisense inhibition” refers to the production of antisense RNA transcripts capable of

suppressing the expression of the target protein. "Overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

A "protein" or "polypeptide" is a chain of amino acids arranged in a specific order determined by the coding sequence in a polynucleotide encoding the polypeptide. Each protein or polypeptide has a unique function.

"Altered levels" or "altered expression" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

"Null mutant" refers here to a host cell which either lacks the expression of a certain polypeptide or expresses a polypeptide which is inactive or does not have any detectable expected enzymatic function.

"Mature protein" or the term "mature" when used in describing a protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor protein" or the term "precursor" when used in describing a protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

A "chloroplast transit peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types present in the cell in which the protein is made. "Chloroplast transit sequence" refers to a nucleotide sequence that encodes a chloroplast transit peptide. A "signal peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53). If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*) may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

"Transformation" refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or "gene gun" transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050,

incorporated herein by reference). Thus, isolated polynucleotides of the present invention can be incorporated into recombinant constructs, typically DNA constructs, capable of introduction into and replication in a host cell. Such a construct can be a vector that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. A number of vectors suitable for stable transfection of plant cells or for the establishment of transgenic plants have been described in, e.g., Pouwels et al., *Cloning Vectors: A Laboratory Manual*, 1985, supp. 1987; Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989; and Flevin et al., *Plant Molecular Biology Manual*, Kluwer Academic Publishers, 1990. Typically, plant expression vectors include, for example, one or more cloned plant genes under the transcriptional control of 5' and 3' regulatory sequences and a dominant selectable marker. Such plant expression vectors also can contain a promoter regulatory region (e.g., a regulatory region controlling inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter "Maniatis").

"PCR" or "polymerase chain reaction" is well known by those skilled in the art as a technique used for the amplification of specific DNA segments (U.S. Patent Nos. 4,683,195 and 4,800,159).

The present invention concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) first nucleotide sequence encoding a polypeptide of at least 126 amino acids having at least 50% identity based on the Clustal method of alignment when compared to a polypeptide consisting of SEQ ID NO:2, or preferably 369 amino acids having at least 82% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:4, 6, and 8, or (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

Preferably, the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7, that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, and 8.

Nucleic acid fragments encoding at least a portion of several sterol delta-14 reductase have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST

algorithms well known to those skilled in the art. The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other plant sterol delta-14 reductase, either as cDNAs or genomic DNAs, could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, an entire sequence can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primer DNA labeling, nick translation, end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of appropriate stringency.

In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673-5677; Loh et al. (1989) *Science* 243:217-220). Products generated by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165). Consequently, a polynucleotide comprising a nucleotide sequence of at least one of 300 (preferably one of at least 200, most preferably

one of at least 125) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7 and the complement of such nucleotide sequences may be used in such methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a polypeptide.

5       The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of a plant sterol delta-14 reductase polypeptide, preferably a substantial portion of a plant sterol delta-14 reductase polypeptide, comprising the steps of : synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous  
10       nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7, and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a portion of a plant sterol delta-14 reductase polypeptide.

15       Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then  
20       be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36:1-34; Maniatis).

      In another embodiment, this invention concerns viruses and host cells comprising either the chimeric genes of the invention as described herein or an isolated polynucleotide of the invention as described herein. Examples of host cells which can be used to practice  
25       the invention include, but are not limited to, yeast, bacteria, and plants.

      As was noted above, the nucleic acid fragments of the instant invention may be used to create transgenic plants in which the disclosed polypeptides are present at higher or lower levels than normal or in cell types or developmental stages in which they are not normally found. This would have the effect of altering the level of phytosterols in those cells.

30       Overexpression of the proteins of the instant invention may be accomplished by first constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of development. The chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding transcription  
35       termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the instant isolated polynucleotide (or chimeric gene) may be constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and  
5 propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by  
10 Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

For some applications it may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate its secretion from the cell. It is thus envisioned that the chimeric gene described above may be further supplemented by directing the coding  
15 sequence to encode the instant polypeptides with appropriate intracellular targeting sequences such as transit sequences (Keegstra (1989) *Cell* 56:247-253), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel (1992) *Plant Phys.* 100:1627-1632) with or without removing targeting sequences that are already present.  
20 While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of use may be discovered in the future.

It may also be desirable to reduce or eliminate expression of genes encoding the instant polypeptides in plants for some applications. In order to accomplish this, a chimeric gene designed for co-suppression of the instant polypeptide can be constructed by linking a  
25 gene or gene fragment encoding that polypeptide to plant promoter sequences. Alternatively, a chimeric gene designed to express antisense RNA for all or part of the instant nucleic acid fragment can be constructed by linking the gene or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the  
30 corresponding endogenous genes are reduced or eliminated.

Molecular genetic solutions to the generation of plants with altered gene expression have a decided advantage over more traditional plant breeding approaches. Changes in plant phenotypes can be produced by specifically inhibiting expression of one or more genes by antisense inhibition or cosuppression (U.S. Patent Nos. 5,190,931, 5,107,065 and  
35 5,283,323). An antisense or cosuppression construct would act as a dominant negative regulator of gene activity. While conventional mutations can yield negative regulation of gene activity these effects are most likely recessive. The dominant negative regulation

available with a transgenic approach may be advantageous from a breeding perspective. In addition, the ability to restrict the expression of a specific phenotype to the reproductive tissues of the plant by the use of tissue specific promoters may confer agronomic advantages relative to conventional mutations which may have an effect in all tissues in which a mutant gene is ordinarily expressed.

The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. For example, the proper level of expression of sense or antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan. Once transgenic plants are obtained by one of the methods described above, it will be necessary to screen individual transgenics for those that most effectively display the desired phenotype. Accordingly, the skilled artisan will develop methods for screening large numbers of transformants. The nature of these screens will generally be chosen on practical grounds. For example, one can screen by looking for changes in gene expression by using antibodies specific for the protein encoded by the gene being suppressed, or one could establish assays that specifically measure enzyme activity. A preferred method will be one which allows large numbers of samples to be processed rapidly, since it will be expected that a large number of transformants will be negative for the desired phenotype.

In another embodiment, the present invention concerns a polypeptide of at least 126 amino acids having at least 50% identity based on the Clustal method of alignment when compared to a polypeptide consisting of SEQ ID NO:2, or preferably 369 amino acids having at least 82% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:4, 6, and 8.

The instant polypeptides (or portions thereof) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to these proteins by methods well known to those skilled in the art. The antibodies are useful for detecting the polypeptides of the instant invention *in situ* in cells or *in vitro* in cell extracts. Preferred heterologous host cells for production of the instant polypeptides are microbial hosts. Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct a chimeric gene for production of the instant polypeptides. This chimeric gene could then be introduced into appropriate microorganisms via transformation to provide high level expression of the encoded sterol delta-14 reductase. An example of a vector for high level expression of the instant polypeptides in a bacterial host is provided (Example 6).

Additionally, the instant polypeptides can be used as a target to facilitate design and/or identification of inhibitors of those enzymes that may be useful as herbicides. This is



desirable because the polypeptides described herein catalyzes an important step in phytosterol biosynthesis. Accordingly, inhibition of the activity of one or more of the enzymes described herein could lead to inhibition of plant growth. Thus, the instant polypeptides could be appropriate for new herbicide discovery and design.

5 All or a substantial portion of the polynucleotides of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and used as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP)  
10 markers. Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe  
15 Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

20 The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4:37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals  
25 may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

30 In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Res.* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

35 A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 11:95-96), polymorphism

of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nat. Genet.* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Loss of function mutant phenotypes may be identified for the instant cDNA clones either by targeted gene disruption protocols or by identifying specific mutants for these genes contained in a maize population carrying mutations in all possible genes (Ballinger and Benzer (1989) *Proc. Natl. Acad. Sci USA* 86:9402-9406; Koes et al. (1995) *Proc. Natl. Acad. Sci USA* 92:8149-8153; Bensen et al. (1995) *Plant Cell* 7:75-84). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the plant gene encoding the instant polypeptides. Alternatively, the instant nucleic acid fragment may be used as a hybridization probe against PCR amplification products generated from the mutation population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the endogenous gene encoding the instant polypeptides can be identified and obtained. This mutant plant can then be used to determine or confirm the natural function of the instant polypeptides disclosed herein.

### 30 EXAMPLES

The present invention is further defined in the following Examples, in which parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, various modifications of the

invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

The disclosure of each reference set forth herein is incorporated herein by reference in its entirety.

### EXAMPLE 1

#### Composition of cDNA Libraries; Isolation and Sequencing of cDNA Clones

cDNA libraries representing mRNAs from various corn and soybean tissues were prepared. The characteristics of the libraries are described below.

TABLE 2

cDNA Libraries from Corn and Soybean

Library	Tissue	Clone
p0097	V9 7cm whorl section + ECB1, screened 1 B73+ECB1: 7-cm whorl section Growth conditions: field plots; these plants have been infested with ECB four times prior to harvest. Growth stage: unknown; V9 or V10	p0097.cqrau67ra: fis
src3c	Soybean 8 day old root infected with cyst nematode	src3c.pk009.c1
ssm	Soybean Shoot Meristem	ssm.pk0031.d12: fis

cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA libraries in Uni-ZAP™ XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAP™ XR libraries are converted into plasmid libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the plasmid vector pBluescript. In addition, the cDNAs may be introduced directly into precut Bluescript II SK(+) vectors (Stratagene) using T4 DNA ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing recombinant pBluescript plasmids, or the insert cDNA sequences are amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams et al., (1991) *Science* 252:1651-1656). The resulting ESTs are analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

Full-insert sequence (FIS) data is generated utilizing a modified transposition protocol. Clones identified for FIS are recovered from archived glycerol stocks as single

colonies, and plasmid DNAs are isolated via alkaline lysis. Isolated DNA templates are reacted with vector primed M13 forward and reverse oligonucleotides in a PCR-based sequencing reaction and loaded onto automated sequencers. Confirmation of clone identification is performed by sequence alignment to the original EST sequence from which the FLS request is made.

Confirmed templates are transposed via the Primer Island transposition kit (PE Applied Biosystems, Foster City, CA) which is based upon the *Saccharomyces cerevisiae* Ty1 transposable element (Devine and Boeke (1994) *Nucleic Acids Res.* 22:3765-3772). The *in vitro* transposition system places unique binding sites randomly throughout a population of large DNA molecules. The transposed DNA is then used to transform DH10B electro-competent cells (Gibco BRL/Life Technologies, Rockville, MD) via electroporation. The transposable element contains an additional selectable marker (named DHFR; Fling and Richards (1983) *Nucleic Acids Res.* 11:5147-5158), allowing for dual selection on agar plates of only those subclones containing the integrated transposon. Multiple subclones are randomly selected from each transposition reaction, plasmid DNAs are prepared via alkaline lysis, and templates are sequenced (ABI Prism dye-terminator ReadyReaction mix) outward from the transposition event site, utilizing unique primers specific to the binding sites within the transposon.

Sequence data is collected (ABI Prism Collections) and assembled using Phred/Phrap (P. Green, University of Washington, Seattle). Phrep/Phrap is a public domain software program which re-reads the ABI sequence data, re-calls the bases, assigns quality values, and writes the base calls and quality values into editable output files. The Phrap sequence assembly program uses these quality values to increase the accuracy of the assembled sequence contigs. Assemblies are viewed by the Consed sequence editor (D. Gordon, University of Washington, Seattle).

## EXAMPLE 2

### Identification of cDNA Clones

cDNA clones encoding sterol delta-14 reductase were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also [www.ncbi.nlm.nih.gov/BLAST/](http://www.ncbi.nlm.nih.gov/BLAST/)) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all

publicly available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value. Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

ESTs submitted for analysis are compared to the genbank database as described above. ESTs that contain sequences more 5- or 3-prime can be found by using the BLASTn algorithm (Altschul et al (1997) *Nucleic Acids Res.* 25:3389-3402.) against the Du Pont proprietary database comparing nucleotide sequences that share common or overlapping regions of sequence homology. Where common or overlapping sequences exist between two or more nucleic acid fragments, the sequences can be assembled into a single contiguous nucleotide sequence, thus extending the original fragment in either the 5 or 3 prime direction. Once the most 5-prime EST is identified, its complete sequence can be determined by Full Insert Sequencing as described in Example 1. Homologous genes belonging to different species can be found by comparing the amino acid sequence of a known gene (from either a proprietary source or a public database) against an EST database using the tBLASTn algorithm. The tBLASTn algorithm searches an amino acid query against a nucleotide database that is translated in all 6 reading frames. This search allows for differences in nucleotide codon usage between different species, and for codon degeneracy.

### EXAMPLE 3

#### Characterization of cDNA Clones Encoding Sterol Delta-14 Reductase

The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the polypeptides encoded by the cDNAs to soybean sterol delta-14 reductase from *Ascomobolus immersus* (Genbank Accession No. 1805625). Shown in Table 3 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), the sequences of contigs assembled from two or more ESTs ("Contig"), sequences of contigs assembled from an FIS and one or more ESTs ("Contig\*"), or sequences encoding an entire protein derived from an FIS, a contig, or an FIS and PCR ("CGS"):

TABLE 3  
BLAST Results for Sequences Encoding Polypeptides Homologous  
to Soybean Sterol Delta-14 Reductase

Clone	Status	BLAST pLog Score [gi 1805625]
src3c.pk009.c1	EST	6.70

5           The sequence of the entire cDNA insert in the clones listed in Table 3 was  
determined. Further sequencing and searching of the DuPont proprietary database allowed  
the identification of other corn and soybean clones encoding sterol delta-14 reductase. The  
BLASTX search using the EST sequences from clones listed in Table 4 revealed similarity  
of the polypeptides encoded by the cDNAs to sterol delta-14 reductases from *Arabidopsis*  
10 *thaliana* (NCBI General Identifier Nos. gi 8917585 and gi 8980704). Shown in Table 4 are  
the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts  
comprising the indicated cDNA clones ("FIS"), sequences of contigs assembled from two or  
more ESTs ("Contig"), sequences of contigs assembled from an FIS and one or more ESTs  
("Contig\*"), or sequences encoding the entire protein derived from an FIS, a contig, or an  
15 FIS and PCR ("CGS"):

TABLE 4  
BLAST Results for Sequences Encoding Polypeptides Homologous  
to *Arabidopsis* Sterol Delta-14 Reductases

Clone	Status	BLAST pLog Score gi 8917585
p0097.cqrau67ra:fis	FIS	62.70
src3c.pk009.c1:fis	FIS	>180.00
ssm.pk0031.d12:fis	FIS	174.00

20           Figure 1 presents an alignment of the amino acid sequences set forth in SEQ ID  
NOs:4, 6, and 8, and the *Arabidopsis thaliana* sequence (SEQ ID NO:10). The data in  
Table 5 represents a calculation of the percent identity of the amino acid sequences set forth  
25 in SEQ ID NOs:2, 4, 6, and 8, and the *Ascobolus immersus* and the *Arabidopsis thaliana*  
sequences (SEQ ID NOs:9 and 10). The nucleotide and polypeptide sequences contained in  
SEQ ID NOs:1 and 2, respectively, were part of the provisional filing of this application  
(U.S. Provisional Application No. 60/156820, filed September 30, 1999). The closest art at  
the time of the provisional filing was the *Ascobolus immersus* enzyme. The *Arabidopsis*  
30 Genbank submission is dated July 5, 2000. The percent identity of SEQ ID NO:2 to the

*Arabidopsis thaliana* sequence (SEQ ID NO:10, Jang et al. (2000) *Genes Dev.* 14:1485-1497) is 64.3%.

**TABLE 5**

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to Sterol Delta-14 Reductases

SEQ ID NO.	Percent Identity to	
	gi 1805625	gi 8917585
2	21.4%	
4		76.4%
6		81.1%
8		78.6%

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*. 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of a sterol delta-14 reductase. These sequences represent the first plant (SEQ ID NO:2) and first corn and soybean sequences encoding sterol delta-14 reductase known to Applicant.

#### **EXAMPLE 4**

##### **Expression of Chimeric Genes in Monocot Cells**

A chimeric gene comprising a cDNA encoding the instant polypeptides in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from

pML103 contains a 1.05 kb Sall-NcoI promoter fragment of the maize 27 kD zein gene and a 0.96 kb SmaI-Sall fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli* XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding the instant polypeptides, and the 10 kD zein 3' region.

The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al. (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236) which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be used to transfer genes to the callus culture cells. According to this method, gold particles (1 µm in diameter) are coated with DNA using the following technique. Ten µg of plasmid DNAs are added to 50 µL of a suspension of gold particles (60 mg per mL). Calcium chloride (50 µL of a 2.5 M solution) and spermidine free base (20 µL of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200 µL of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles



resuspended in a final volume of 30  $\mu$ L of ethanol. An aliquot (5  $\mu$ L) of the DNA-coated gold particles can be placed in the center of a Kapton™ flying disc (Bio-Rad Labs). The particles are then accelerated into the corn tissue with a Biolistic™ PDS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

Seven days after bombardment the tissue can be transferred to N6 medium that contains glufosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing glufosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

#### EXAMPLE 5

##### Expression of Chimeric Genes in Dicot Cells

A seed-specific expression cassette composed of the promoter and transcription terminator from the gene encoding the  $\beta$  subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin cassette includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire cassette is flanked by Hind III sites.

The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment

when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

Soybean embryos may then be transformed with the expression vector comprising sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can be maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70-73, U.S. Patent No. 4,945,050). A DuPont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al. (1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed expression cassette comprising the phaseolin 5' region, the fragment encoding the instant polypeptides and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

To 50 µL of a 60 mg/mL 1 µm gold particle suspension is added (in order): 5 µL DNA (1 µg/µL), 20 µL spermidine (0.1 M), and 50 µL CaCl<sub>2</sub> (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 µL 70% ethanol and resuspended in 40 µL of anhydrous ethanol. The DNA/particle suspension can be sonicated three times for one second each. Five µL of the DNA-coated gold particles are then loaded on each macro carrier disk.

Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally

bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

- 5 Five to seven days post bombardment, the liquid media may be exchanged with fresh media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into
- 10 individual flasks to generate new, clonally propagated, transformed embryogenic suspension cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

#### EXAMPLE 6

##### Expression of Chimeric Genes in Microbial Cells

- 15 The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in
- 20 pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region,
- 25 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

- Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% low melting agarose gel. Buffer and agarose contain 10 µg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel
- 30 by digestion with GELase™ (Epicentre Technologies, Madison, WI) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs (NEB), Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The
- 35 vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5

electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptides are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio-β-galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by centrifugation and re-suspended in 50 µL of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One µg of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.

#### EXAMPLE 7

##### Evaluating Compounds for Their Ability to Inhibit the Activity of Sterol Delta-14 Reductase

The polypeptides described herein may be produced using any number of methods known to those skilled in the art. Such methods include, but are not limited to, expression in bacteria as described in Example 6, or expression in eukaryotic cell culture, *in planta*, and using viral expression systems in suitably infected organisms or cell lines. The instant polypeptides may be expressed either as mature forms of the proteins as observed *in vivo* or as fusion proteins by covalent attachment to a variety of enzymes, proteins or affinity tags. Common fusion protein partners include glutathione S-transferase ("GST"), thioredoxin ("Trx"), maltose binding protein, and C- and/or N-terminal hexahistidine polypeptide ("His<sub>6</sub>"). The fusion proteins may be engineered with a protease recognition site at the fusion point so that fusion partners can be separated by protease digestion to yield intact mature enzyme. Examples of such proteases include thrombin, enterokinase and factor Xa. However, any protease can be used which specifically cleaves the peptide connecting the fusion protein and the enzyme.

Purification of the instant polypeptides, if desired, may utilize any number of separation technologies familiar to those skilled in the art of protein purification. Examples of such methods include, but are not limited to, homogenization, filtration, centrifugation, heat denaturation, ammonium sulfate precipitation, desalting, pH precipitation, ion exchange

chromatography, hydrophobic interaction chromatography and affinity chromatography, wherein the affinity ligand represents a substrate, substrate analog or inhibitor. When the instant polypeptides are expressed as fusion proteins, the purification protocol may include the use of an affinity resin which is specific for the fusion protein tag attached to the expressed enzyme or an affinity resin containing ligands which are specific for the enzyme. For example, the instant polypeptides may be expressed as a fusion protein coupled to the C-terminus of thioredoxin. In addition, a (His)<sub>6</sub> peptide may be engineered into the N-terminus of the fused thioredoxin moiety to afford additional opportunities for affinity purification. Other suitable affinity resins could be synthesized by linking the appropriate ligands to any suitable resin such as Sepharose-4B. In an alternate embodiment, a thioredoxin fusion protein may be eluted using dithiothreitol; however, elution may be accomplished using other reagents which interact to displace the thioredoxin from the resin. These reagents include  $\beta$ -mercaptoethanol or other reduced thiol. The eluted fusion protein may be subjected to further purification by traditional means as stated above, if desired. Proteolytic cleavage of the thioredoxin fusion protein and the enzyme may be accomplished after the fusion protein is purified or while the protein is still bound to the ThioBond™ affinity resin or other resin.

Crude, partially purified or purified enzyme, either alone or as a fusion protein, may be utilized in assays for the evaluation of compounds for their ability to inhibit enzymatic activation of the instant polypeptides disclosed herein. Assays may be conducted under well known experimental conditions which permit optimal enzymatic activity. For example, assays for sterol delta-14 reductase are presented by Steel (1991) *J Chromatogr* 31:435-43.

CLAIMS

What is claimed is:

1. An isolated polynucleotide selected from the group consisting of:
  - (a) a first nucleotide sequence encoding a polypeptide of at least  
5 126 amino acids having a sequence identity of at least 50% based on  
the Clustal method of alignment when compared to a polypeptide  
consisting of SEQ ID NO:2, and
  - (b) a second nucleotide sequence encoding a polypeptide of at least  
10 369 amino acids having a sequence identity of at least 82% based on  
the Clustal method of alignment when compared to a polypeptide  
selected from the group consisting of SEQ ID NOS:4, 6, and 8.
2. A polynucleotide sequence of Claim 1, wherein sequence identity is at least 85%.
3. A polynucleotide sequence of Claim 1, wherein sequence identity is at least 90%.
4. A polynucleotide sequence of Claim 1, wherein sequence identity is at least 95%.
- 15 5. The polynucleotide of Claim 1 wherein the polynucleotide encodes a polypeptide  
selected from the group consisting of SEQ ID NOS:2, 4, 6, and 8.
6. An isolated polynucleotide comprising a nucleotide sequence of at least  
125 contiguous nucleotides from a nucleotide sequence selected from the group consisting of  
SEQ ID NOS:1, 3, 5, and 7.
- 20 7. The polynucleotide of Claim 6, wherein the polynucleotide comprises a  
nucleotide sequence selected from the group consisting of SEQ ID NO:1, 3, 5, and 7.
8. The polynucleotide of Claim 1, wherein the polypeptide is a
9. An isolated complement of the polynucleotide of Claim 1, wherein (a) the  
complement and the polynucleotide consist of the same number of nucleotides, and (b) the  
25 nucleotide sequences of the complement and the polynucleotide have 100%  
complementarity.
10. An isolated nucleic acid molecule that hybridizes with the isolated  
polynucleotide of Claim 1 under a hybridization condition of 0.1X SSC, 0.1% SDS, and  
65°C.
- 30 11. A cell comprising the polynucleotide of Claim 1.
12. The cell of Claim 11, wherein the cell is selected from the group consisting of a  
yeast cell, a bacterial cell and a plant cell.
13. A transgenic plant comprising the polynucleotide of Claim 1.
14. A method for transforming a cell comprising introducing into a cell the  
35 polynucleotide of Claim 1.

15. A method for producing a transgenic plant comprising (a) transforming a plant cell with the polynucleotide of Claim 1, and (b) regenerating a plant from the transformed plant cell.

5 16. A method for producing a polynucleotide fragment comprising (a) selecting a nucleotide sequence comprised by the polynucleotide of Claim 1, and (b) synthesizing a polynucleotide fragment containing the nucleotide sequence.

17. The method of Claim 16, wherein the fragment is produced *in vivo*.

10 18. An isolated polypeptide selected from the group consisting of (a) a first polypeptide of at least 126 amino acids having a sequence identity of at least 50% based on the Clustal method of alignment when compared to a polypeptide consisting of SEQ ID NO:2, and (b) a second polypeptide of at least 369 amino acids having a sequence identity of at least 82% based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:4, 6, and 8.

15 19. The polypeptide of Claim 18, wherein the sequence identity is at least 85%.

20. The polypeptide of Claim 19, wherein the sequence identity is at least 90%.

21. The polypeptide of Claim 19, wherein the sequence identity is at least 95%.

22. The polypeptide of Claim 19 wherein the polypeptide has a sequence selected from the group consisting of SEQ ID NOs:2, 4, 6, and 8.

20 23. The polypeptide of Claim 18, wherein the polypeptide is a sterol delta-14 reductase.

24. A chimeric gene comprising the polynucleotide of Claim 1 operably linked to at least one suitable regulatory sequence.

25. A method for altering the level of sterol delta-14 reductase expression in a host cell, the method comprising:

25 (a) Transforming a host cell with the chimeric gene of Claim 24; and  
(b) Growing the transformed cell in step (a) under conditions suitable for the expression of the chimeric gene.

26. The method of Claim 25 wherein the isolated polynucleotide consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, and 7.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 9/02, 15/53, 15/63, 1/21, 15/09,</b> <b>15/10, C12Q 1/68, 1/26</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 97/48793</b> <b>(43) International Publication Date:</b> 24 December 1997 (24.12.97)
<b>(21) International Application Number:</b> PCT/US97/10644 <b>(22) International Filing Date:</b> 20 June 1997 (20.06.97)  <b>(30) Priority Data:</b> 60/022,086                      21 June 1996 (21.06.96)                      US  <b>(71) Applicant:</b> THE GENERAL HOSPITAL CORPORATION [US/US]; 55 Fruit Street, Boston, MA 02114 (US).  <b>(72) Inventors:</b> JANG, Jyan-Chyun; The General Hospital Corpora- tion, 55 Fruit Street, Boston, MA 02114 (US). SHEEN, Jen; The General Hospital Corporation, 55 Fruit Street, Boston, MA 02114 (US).  <b>(74) Agent:</b> ELBING, Karen, L.; Clark & Elbing LLP, 176 Federal Street, Boston, MA 02110-2214 (US).		<b>(81) Designated States:</b> AU, CA, CN, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> PLANT STEROL REDUCTASES AND USES THEREOF  <b>(57) Abstract</b>  Disclosed are plant sterol biosynthetic enzymes, genes, and their uses.		



FIGURE 1 Comparison of the Corn, Soybean (2), and Arabidopsis Sterol Delta-14 Reductases

```

p0097.cqrau67ra_fis.PRO
src3c.pk009.c1_fis.PRO
ssm.pk0031.d12_fis.PRO
8917585_(Arabidopsis).PRO
-----MESHVDLGLLQALTPSWNSVPLLVG-----
M-----MESHVDLGLLQALTPSWNSVPLLVG-----
M-----MESHVDLGLLQALTPSWNSVPLLVG-----
M-----DLGVLLPSL-----QSVYVLVF-----

p0097.cqrau67ra_fis.PRO
src3c.pk009.c1_fis.PRO
ssm.pk0031.d12_fis.PRO
8917585_(Arabidopsis).PRO
-----FFTYLAVAGSILPGKLVPGVALLDGTRLHYCCNGLLSLLLVALLGIGA
-----FFTYLAVAGSILPGKLVPGVALLDGTRLHYCCNGLLSLLLVALLGIGA
-----YFVYLAVAGEILPGKVIRGVLLSDGSQRLRYRCNGLLALILVAILGICA
-----PRVR-----KNKVELSLSLANLC-

p0097.cqrau67ra_fis.PRO
src3c.pk009.c1_fis.PRO
ssm.pk0031.d12_fis.PRO
8917585_(Arabidopsis).PRO
-----AISDRGLELLSTTFASFVLVTLILHFGCKSQSKGSS--LKPH-LSG
-----AISDRGLELLSTTFASFVLVTLILHFGCKSQSKGSS--LKPH-LSG
-----VVADRGLELLSATFIFCVLVTLALVYVTVGRSSSNKGSS--LKPH-VSG
-----KMGFVSPT-----
KMGFVSPT-----AISDRGLELLSTTFASFVLVTLILHFGCKSQSKGSS--LKPH-LSG
KMGFVSPT-----AISDRGLELLSTTFASFVLVTLILHFGCKSQSKGSS--LKPH-LSG
KLGIVSPL-----VVADRGLELLSATFIFCVLVTLALVYVTVGRSSSNKGSS--LKPH-VSG

p0097.cqrau67ra_fis.PRO
src3c.pk009.c1_fis.PRO
ssm.pk0031.d12_fis.PRO
8917585_(Arabidopsis).PRO
-----NLIHDWWFGIQLNPQFMG-IDLKFFF-VRAGMMGWLLINLSILMKSIQ-DGTLSQSMILY
-----NLIHDWWFGIQLNPQFMG-IDLK-----AGMMGWLLINLSILMKSIQ-DGTLSQSMILY
-----NLVHDWWFGIQLNPQFMS-IDLKFFF-VRAGMMGWLLINLSILAKSVQ-DGSLSQSMILY

p0097.cqrau67ra_fis.PRO
src3c.pk009.c1_fis.PRO
ssm.pk0031.d12_fis.PRO
8917585_(Arabidopsis).PRO
-----QLFCALYILDYFVHEEYMTSTWDIIAERLGFMLVFGDLVWIPFFSIQGWLLMNSVELT
-----QLFCALYILDYFVHEEYMTSTWDIIAERLGFMLVFGDLVWIPFFSIQGWLLMNSVELT
-----QIFCALYILDYFVHEEYMTSTWDIIAERLGFMLVFGDLLWIPFTFSIQGWLLHNKVELT

p0097.cqrau67ra_fis.PRO
src3c.pk009.c1_fis.PRO
ssm.pk0031.d12_fis.PRO
8917585_(Arabidopsis).PRO
-----IFLIGYLVFRGANKQKHVEKKDKAPIWGKPPKVV---GGKLLASGYWGIA
-----PAAIVANCEFVLIGYMVFRGANKQKHVEKKDKAPIWGKPPKVI---GGKLLASGYWGIA
-----PAAIVANCEFVLIGYMVFRGANKQKHVEKKDKAPIWGKPPKVI---GGKLLASGYWGIA
-----VPAIVVNCLVFLIGYMVFRGANKQKHIFKKNEKPTPIWGKPPVVV---GGKLLVSGYWGIA

```

FIGURE 1 (page 2 of 2)

p0097.cqrau67ra_fis.PRO	RHCNYLGDLALLALSFSLPCGVSSVVPYFYPTYLLILLVLRERRDEARCSQKYREIWAEEYC
src3c.pk009.cl_fis.PRO	RHCNYLGDLMLALSFSLPCGISSPIPYFYPIYLLILLIWRERRDEARCAEKYREIWAEEYR
ssm.pk0031.d12_fis.PRO	RHCNYLGDLMLALSFSLPCGISSPIPYFYPIYLLILLIWRERTDEARCAEKYREIWAEEYR
8917585_(Arabidopsis).PRO	RHCNYLGDLMLALSFSLPCGISSVVPYFYPIYLLILLIWRERRDEVRCAEKYKEIWAEEYL
p0097.cqrau67ra_fis.PRO	KLVPWRILPYVY
src3c.pk009.cl_fis.PRO	KLVPWRILPYVY
ssm.pk0031.d12_fis.PRO	KLVPWRILPYVY
8917585_(Arabidopsis).PRO	RLVPWRILPYVY

## DECLARATION and POWER OF ATTORNEY

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

**GENES ENCODING STEROL DELTA-15 REDUCTASE IN PLANTS**

the specification of which is attached hereto unless the following box is checked:

☒ was filed on **27 September 2000** as U.S. Application No. \_\_\_\_\_ or PCT International Application No. **PCT/US00/26442** and was amended on \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.

Application No.	Country	Filing Date	Priority Claimed (Yes/No)

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States Provisional Application(s) listed below.

U.S. Provisional Application No.

60/156,820

U.S. Filing Date

30 September 1999

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or § 365(c) of any PCT International Application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application or PCT International Application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information which is known to me to be material to patentability as defined in 37 CFR § 1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

Application No.

Filing Date

Status (patented, pending or abandoned)

PCT/US00/26442

27 September 2000

Pending

**POWER OF ATTORNEY:** I hereby appoint the following attorney(s) and/or agent(s) the power to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:Name: **KENING LI**Registration No. **44,872**

Send correspondence and direct telephone calls to:

**KENING LI**
**E. I. du Pont de Nemours and Company**  
**Legal - Patents**  
**Wilmington, DE 19898, U.S.A.**

Tel. No.

(302) 992-3749

Fax No.

(302) 892-1026

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

## INVENTOR(S)

Full Name of Inventor	Last Name	First Name	Middle Name
<b>FAMODU</b>	<b>FAMODU</b>	<b>OMOLAYO</b>	<b>O.</b>
Signature (please sign full name): <i>Omolayo O. Famodu</i>			Date: <i>11/8/00</i>
Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	<b>NEWARK</b>	<b>DELAWARE</b>	<b>U.S.A.</b>
Post Office Address	Post Office Address	City	State or Country
	<b>216 BARRETT RUN PLACE</b>	<b>NEWARK</b>	<b>DELAWARE</b>
			Zip Code
			<b>19702</b>
Full Name of Inventor	Last Name	First Name	Middle Name
<b>KINNEY</b>	<b>KINNEY</b>	<b>ANTHONY</b>	<b>J.</b>
Signature (please sign full name): <i>Anthony Kinney</i>			Date: <i>1 NOV 2000</i>
Residence & Citizenship	City	State or Foreign Country	Country of Citizenship
	<b>WILMINGTON</b>	<b>DELAWARE</b>	<b>UNITED KINGDOM</b>
Post Office Address	Post Office Address	City	State or Country
	<b>609 LORE AVENUE</b>	<b>WILMINGTON</b>	<b>DELAWARE</b>
			Zip Code
			<b>19809</b>

☐ Additional Inventors are being named on separately numbered sheets attached hereto.

GENERAL POWER OF ATTORNEY  
(Concerning Several International Patent Applications)

The undersigned, Vernon R. Rice, Vice President and Assistant General Counsel of E. I. DU PONT DE NEMOURS AND COMPANY, 1007 Marker Street, Wilmington, Delaware 19898 USA ("DuPont"), hereby confirms that the power to sign for DuPont has been granted to various individuals (as set forth in the attached excerpt from DuPont's Patent Board Rules of Procedure (January 1988), Appendix Section III.A.4), including the Chairman, Vice-Chairman, and those individuals who are Assistant Secretaries of the Patent Board. Currently these Assistant Secretaries are:

Roger A. Bowman  
Linda J. Davis  
John E. Griffiths

Barbara J. Massie  
Miriam D. McConnahey  
Deborah A. Meginniss

In addition, the authority to act on behalf of DuPont before the competent International Authorities in connection with any and all international patent applications filed by it with the United States as Receiving Office and to make or receive payments on its behalf is hereby granted to:

Beardell, Lori Y.	34,293	Katz, Elliott A.	26,396
Belopolsky, Inna	43,319	Kelly, Patricia L.	39,247
Benjamin, Steven C.	36,087	King, Karen K.	34,850
Birch, Linda D.	38,719	Kuller, Mark D.	31,925
Bowen, Jr., Alanson G.	24,027	Krukiel, Charles E.	27,344
Christenbury, Lynne M.	30,971	Jarnholm, Arne R.	30,396
Cotreau, William J.	36,490	Langworthy, John A.	32,255
Deitch, Gerald E.	30,457	Lerman, Bart E.	31,897
Deshmukh, Sudhir	33,677	Levitt, Cary A.	31,848
Dobson, Kevin S.	40,296	Magee, Thomas H.	27,355
Duffy, Roseanne R.	33,869	Mayer, Nancy S.	29,190
Edwards, Mark A.	39,542	Medwick, George M.	27,456
Estrin, Barry	26,452	Morrisey, Bruce W.	30,663
Evans, Craig H.	31,825	Reynolds, Stephen E.	37,580
Fair, Tamara L.	35,867	Rizzo, Thomas M.	41,272
Feltham, S. Neil	36,506	Santopietro, Lois A.	36,264
Floyd, Linda Axamethy	33,692	Schaeffer, Andrew L.	33,605
Fricke, Hilmar L.	22,384	Sebree, Chyrtrea J.	45,348
Furr, Robert B.	32,985	Shay, Lucas K.	34,724
Golian, Andrew G.	25,293	Shipley, James E.	32,003
Golian, Paul D.	42,591	Siegell, Barbara C.	30,684
Gorman, Thomas W.	31,959	Sinnott, Jessica M.	34,015
Gould, David J.	25,338	Steinberg, Michael A.	43,160
Griffiths, John E.	32,647	Steinberg, Thomas W.	37,013
Hamby, Jane O.	32,872	Stevenson, Robert B.	26,039
Hamby, William H.	31,521	Strickland, Frederick D.	39,041
Heiser, David E.	31,366	Tulloch, Rebecca W.	36,297
Hendrickson, John S.	30,847	Walker, P. Michael	32,602
Joung, J. Kenneth	41,881	Wang, Chen	38,650

The undersigned ratifies fully all actions already taken by the above-named individuals in accordance with the authority granted hereby.

E. I. DU PONT DE NEMOURS AND COMPANY

By: 

Vernon R. Rice  
Vice President and Assistant General Counsel

0-6-01

SEQUENCE LISTING

&lt;110&gt; E.I. du Pont de Nemours and Company

&lt;120&gt; Genes Encoding Sterol Delta-14 Reductase in Plants

&lt;130&gt; BB1395 PCT

&lt;140&gt;

&lt;141&gt;

&lt;150&gt; 60/156,820

&lt;151&gt; 1999-09-30

&lt;160&gt; 10

&lt;170&gt; Microsoft Office 95

&lt;210&gt; 1

&lt;211&gt; 427

&lt;212&gt; DNA

&lt;213&gt; Glycine max

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (360)

&lt;400&gt; 1

```

gtgatgatgg agtcacacgt ggatctaggt tttctccttc aagctctcac tccatcttgg 60
aactccgttc ctttgcttgg ggggttcttc acttaacttg ccttgctgga atccattctc 120
cctggaaaac ttgttccctg cgttgcaacta ctcgatggaa ctgctctaca ctattgctgc 180
aatggtctgc tctcgcttct tctgttggtt gcacttctcg ggatcgggtc caagatgggt 240
tttgtgtctc ccaactgccat atcaaacaga ggacttgagc tgctgtccac aacttttgcc 300
ttcagttttc ttgtaacctt gatattgcat ttttccgggt gcaagtcaca aagtaaaggn 360
tcatactaa agcctcatct cagtgggaac ctgatacacg attggtggtt tgggaatata 420
actaaaa

```

&lt;210&gt; 2

&lt;211&gt; 126

&lt;212&gt; PRT

&lt;213&gt; Glycine max

&lt;400&gt; 2

```

Leu Gln Ala Leu Thr Pro Ser Trp Asn Ser Val Pro Leu Leu Val Gly
 1              5              10              15
Phe Phe Thr Tyr Leu Ala Val Ala Gly Ser Ile Leu Pro Gly Lys Leu
          20              25              30
Val Pro Gly Val Ala Leu Leu Asp Gly Thr Arg Leu His Tyr Cys Cys
          35              40              45
Asn Gly Leu Leu Ser Leu Leu Leu Leu Val Ala Leu Leu Gly Ile Gly
          50              55              60
Ala Lys Met Gly Phe Val Ser Pro Thr Ala Ile Ser Asn Arg Gly Leu
          65              70              75              80

```

WO 01/23539

PCT/US00/26442

Glu Leu Leu Ser Thr Thr Phe Ala Phe Ser Phe Leu Val Thr Leu Ile  
85 90 95

Leu His Phe Ser Gly Cys Lys Ser Gln Ser Lys Gly Ser Ser Leu Lys  
100 105 110

Pro His Leu Ser Gly Asn Leu Ile His Asp Trp Trp Phe Gly  
115 120 125

<210> 3  
<211> 1631  
<212> DNA  
<213> Glycine max

<400> 3  
ccgcgttggga atttgcccat ctaaaacctc aatcttttac tgaaaagtct caactttgaa 60  
ctcactcgaa gtgatgatgg agtcacacgt ggatctagggt tttctccttc aagctctcac 120  
tccatcttgg aactccgttc ctttgccttg ggggttcttc acttacttgg ccgttgctgg 180  
atccattctc cctggaaaac ttgttccttg cgttgcaacta ctcgatggaa ctgctctaca 240  
ctattgctgc aatggctcgc tctcgcttct tctgttggtt gcacttctcg ggatcggtgc 300  
caagatgggt tttgtgtctc ccactgccat atcagacaga ggacttgagc tgctgtccac 360  
aacttttgcc ttcagttttc ttgtaaccct gatattgcat ttttccggtt gcaagtcaca 420  
aagtaaaggt tcatcactaa agcctcatct cagtggaaac ctgatacacg attggtgggt 480  
tggtatacaa ctaaataccac agttcatggg tatcgacctc aaatttttct ttgttagagc 540  
tggaatgatg ggatggctac ttatcaattt atctattctt atgaagagca ttcaagatgg 600  
tactttgagc cagtcaatga ttctctacca gctattctgt gcactataca tcctggacta 660  
ttttgtacat gaagagtaca tgacatccac ctgggacata attgcagaga gactgggctt 720  
catgttgggtc tttggagatt tagtgtggat tcctttctct ttcagcatac agggatgggtg 780  
gctcttgatg aacagtgtgg agttaacacc agctgccatt gtagctaatt gctttgtgtt 840  
cctgattgga tacatggtat ttcgaggagc aaacaagcaa aagcatgtgt tcaaaaagaa 900  
tccaaaggct cctatctggg gtaagcctcc aaaagtcatt ggtggaaagc tacttgcttc 960  
tggttattgg ggtattgcta gacactgtaa ttacctaggg gatttgatgc ttgctctctc 1020  
ctttagctta ccatgtggga taagttcacc aattccatac ttctatccaa tttatcttct 1080  
tattctgtta atctggagag agagaaggga tgaagctcgt tgcgccgaga agtatagaga 1140  
gatatgggcc gagtatcgta aacttgttcc atggagaata ttgccttacg tttattagga 1200  
tgaaaaaaaa aagggttcca ccatgaattc ttcactctgc cgatgttatt aagcacttcg 1260  
atgtaaattg gttcttggtc ttgtgggttc aatcttggat cttttcttat tgagccatgt 1320  
agctgcagga gagtggttcg agggatttat ctaccatct atatttgtgt atcattatgc 1380  
tgcagcctgc aggccttcat ttttcaatgg ccaactcttt ttgacttgtt ctatttgttt 1440  
ttagatgaga atttcatggt caaagctcct aggccttaaaa aaacagtgtc atgttctatg 1500  
ggaagtgcag gaagcaattc ggggactgca ggaagcaatt gcctttacat tgatatgctc 1560  
aatggtactt taggcccttt aatgttcttg cttttcattt gtgagttatt attggcccca 1620  
tttcatttgc a 1631

<210> 4  
<211> 374  
<212> PRT  
<213> Glycine max

<400> 4  
Met Met Glu Ser His Val Asp Leu Gly Phe Leu Leu Gln Ala Leu Thr  
1 5 10 15  
Pro Ser Trp Asn Ser Val Pro Leu Leu Val Gly Phe Phe Thr Tyr Leu  
20 25 30  
Ala Val Ala Gly Ser Ile Leu Pro Gly Lys Leu Val Pro Gly Val Ala  
35 40 45

WO 01/23539

PCT/US00/26442

Leu Leu Asp Gly Thr Arg Leu His Tyr Cys Cys Asn Gly Leu Leu Ser  
50 55 60

Leu Leu Leu Leu Val Ala Leu Leu Gly Ile Gly Ala Lys Met Gly Phe  
65 70 75 80

Val Ser Pro Thr Ala Ile Ser Asp Arg Gly Leu Glu Leu Leu Ser Thr  
85 90 95

Thr Phe Ala Phe Ser Phe Leu Val Thr Leu Ile Leu His Phe Ser Gly  
100 105 110

Cys Lys Ser Gln Ser Lys Gly Ser Ser Leu Lys Pro His Leu Ser Gly  
115 120 125

Asn Leu Ile His Asp Trp Trp Phe Gly Ile Gln Leu Asn Pro Gln Phe  
130 135 140

Met Gly Ile Asp Leu Lys Phe Phe Phe Val Arg Ala Gly Met Met Gly  
145 150 155 160

Trp Leu Leu Ile Asn Leu Ser Ile Leu Met Lys Ser Ile Gln Asp Gly  
165 170 175

Thr Leu Ser Gln Ser Met Ile Leu Tyr Gln Leu Phe Cys Ala Leu Tyr  
180 185 190

Ile Leu Asp Tyr Phe Val His Glu Glu Tyr Met Thr Ser Thr Trp Asp  
195 200 205

Ile Ile Ala Glu Arg Leu Gly Phe Met Leu Val Phe Gly Asp Leu Val  
210 215 220

Trp Ile Pro Phe Ser Phe Ser Ile Gln Gly Trp Trp Leu Leu Met Asn  
225 230 235 240

Ser Val Glu Leu Thr Pro Ala Ala Ile Val Ala Asn Cys Phe Val Phe  
245 250 255

Leu Ile Gly Tyr Met Val Phe Arg Gly Ala Asn Lys Gln Lys His Val  
260 265 270

Phe Lys Lys Asn Pro Lys Ala Pro Ile Trp Gly Lys Pro Pro Lys Val  
275 280 285

Ile Gly Gly Lys Leu Leu Ala Ser Gly Tyr Trp Gly Ile Ala Arg His  
290 295 300

Cys Asn Tyr Leu Gly Asp Leu Met Leu Ala Leu Ser Phe Ser Leu Pro  
305 310 315 320

Cys Gly Ile Ser Ser Pro Ile Pro Tyr Phe Tyr Pro Ile Tyr Leu Leu  
325 330 335

Ile Leu Leu Ile Trp Arg Glu Arg Arg Asp Glu Ala Arg Cys Ala Glu  
340 345 350

Lys Tyr Arg Glu Ile Trp Ala Glu Tyr Arg Lys Leu Val Pro Trp Arg  
355 360 365

Ile Leu Pro Tyr Val Tyr  
370

<210> 5  
<211> 667  
<212> DNA  
<213> Zea mays

<400> 5  
ccacgcgtcc ggaagaacaa agtagagctg tcccttttgt ctggctctagc taactttatgc 60  
atcttttctta ttggctacct agtggtccga ggagctaaca agcaaaaaca tgtgttcaag 120  
aaggacccca aagctcctat atggggaaaaa cctcccaaag ttgtcggggg aaagctacta 180  
gcatctggtt actggggcat cgcaaggcac tgcaattatc tcggagacct gctgctagca 240  
ctttcgttca gcttgccctg tggagtgagt tccgtggtcc catacttcta cccacgtac 300  
ctgctcattc tactggtctt gagggaaaagg cgcgatgagg cgaggtgctc gcagaagtac 360  
agggagatct gggcagagta ctgcaagctc gtgccgtgga ggatcctgcc ttatgtgtac 420  
tgaagagacg gtagaaacca aggcagctca tggccctggg ccagctgtaa accttatttt 480  
gtttgccctt aaccagttgg tgaatgttga tgtagcactc ggtaaactgt gaccgtgcaa 540  
acttttgtaa ttgttggtcc atacatgttt ggaatcgtga atcagaccgc ctcacttggg 600  
ggcaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 660  
aaaaaag 667

<210> 6  
<211> 140  
<212> PRT  
<213> Zea mays

<400> 6  
Pro Arg Val Arg Lys Asn Lys Val Glu Leu Ser Leu Leu Ser Gly Leu  
1 5 10 15  
Ala Asn Leu Cys Ile Phe Leu Ile Gly Tyr Leu Val Phe Arg Gly Ala  
20 25 30  
Asn Lys Gln Lys His Val Phe Lys Lys Asp Pro Lys Ala Pro Ile Trp  
35 40 45  
Gly Lys Pro Pro Lys Val Val Gly Gly Lys Leu Leu Ala Ser Gly Tyr  
50 55 60  
Trp Gly Ile Ala Arg His Cys Asn Tyr Leu Gly Asp Leu Leu Leu Ala  
65 70 75 80  
Leu Ser Phe Ser Leu Pro Cys Gly Val Ser Ser Val Val Pro Tyr Phe  
85 90 95  
Tyr Pro Thr Tyr Leu Leu Ile Leu Leu Val Leu Arg Glu Arg Arg Asp  
100 105 110  
Glu Ala Arg Cys Ser Gln Lys Tyr Arg Glu Ile Trp Ala Glu Tyr Cys  
115 120 125  
Lys Leu Val Pro Trp Arg Ile Leu Pro Tyr Val Tyr  
130 135 140



WO 01/23539

PCT/US00/26442

<210> 7  
 <211> 1364  
 <212> DNA  
 <213> Glycine max

<400> 7  
 ttcggcacga gtaaaacctc aatctttttac tgaaaagtct caacttttgaa ctcactcgaa 60  
 gtgatgatgg agtcacacgt ggatctaggt tttctccttc aagctctcac tccatcttgg 120  
 aactccgttc ctttgcttgt ggggttcttc acttacttgg cgttgcttgg atccattctc 180  
 cctggaaaac ttgttcctgg cgttgactta ctcgatggaa ctctgtctaca ctattgctgc 240  
 aatggtctgc tctcgttctt tctgttggtt gcacttctcg ggatcgggtc caagatgggt 300  
 tttgtgtctc ccactgccat atcagacaga ggacttgagc tgctgtccac aacttttgcc 360  
 ttcagttttc ttgtaaccct gatattgcat ttttccgggt gcaagtcaca aagtaaaggt 420  
 tcatcactaa agcctcatct cagtggaaac ctgatacacg attggtggtt tggatacaaa 480  
 ctaaattccac agttcatggg tatcgacctc aaagctggaa tgatgggatg gctacttatc 540  
 aatttatcta ttcttatgaa gagcattcaa gatggtaact tgagccagtc aatgattctc 600  
 taccagctat tctgtgcaat atacatcctg gactattttg tacatgaaga gtacatgaca 660  
 tccacctggg acataattgc agagagactg ggcttcatgt tggcttttgg agatttagtg 720  
 tggattctct tctctttcag catacaggga tgggtggtct tgatgaacag tgtggagtta 780  
 acaccagctg ccattgtagc taattgcttt gtgttctctga ttggatacat ggtatttctga 840  
 ggagcaaaac agcaaaaagca tgtgttcaaa aagaatccaa aggtctctat ctggggtaag 900  
 cctccaaaag tcattggttg aaagctactt gcttctggtt attggggtat tgctagacac 960  
 tgtaattacc taggggattt gatgcttgct ctctccttta gcttaccatg tgggataagt 1020  
 tcaccaattc catacttcta tccaatttat cttcttattc tgtaaatctg gagagagaga 1080  
 acggatgaag ctggttgccg cgagaagtat agagagatat gggccgagta tcgtaaaact 1140  
 gttccatgga gaatattgcc ttacgtttat taggatgaaa aaaaaaaggg cttcaccatg 1200  
 aattcttcat cttgccgatg ttattaagca cttcgatgta aattggttct tgttcttctg 1260  
 gtttcaatct tggatctttt cttattgagc catgtagctg caggagagtg tttcagaggga 1320  
 tttatcttac catctatatt tgtgtaaaaa aaaaaaaaaa aaaa 1364

<210> 8  
 <211> 369  
 <212> PRT  
 <213> Glycine max

<400> 8  
 Met Met Glu Ser His Val Asp Leu Gly Phe Leu Leu Gln Ala Leu Thr  
 1 5 10 15  
 Pro Ser Trp Asn Ser Val Pro Leu Leu Val Gly Phe Phe Thr Tyr Leu  
 20 25 30  
 Ala Val Ala Gly Ser Ile Leu Pro Gly Lys Leu Val Pro Gly Val Ala  
 35 40 45  
 Leu Leu Asp Gly Thr Arg Leu His Tyr Cys Cys Asn Gly Leu Leu Ser  
 50 55 60  
 Leu Leu Leu Leu Val Ala Leu Leu Gly Ile Gly Ala Lys Met Gly Phe  
 65 70 75 80  
 Val Ser Pro Thr Ala Ile Ser Asp Arg Gly Leu Glu Leu Leu Ser Thr  
 85 90 95  
 Thr Phe Ala Phe Ser Phe Leu Val Thr Leu Ile Leu His Phe Ser Gly  
 100 105 110  
 Cys Lys Ser Gln Ser Lys Gly Ser Ser Leu Lys Pro His Leu Ser Gly  
 115 120 125

Asn Leu Ile His Asp Trp Trp Phe Gly Ile Gln Leu Asn Pro Gln Phe  
 130 135 140  
 Met Gly Ile Asp Leu Lys Ala Gly Met Met Gly Trp Leu Leu Ile Asn  
 145 150 155 160  
 Leu Ser Ile Leu Met Lys Ser Ile Gln Asp Gly Thr Leu Ser Gln Ser  
 165 170 175  
 Met Ile Leu Tyr Gln Leu Phe Cys Ala Leu Tyr Ile Leu Asp Tyr Phe  
 180 185 190  
 Val His Glu Glu Tyr Met Thr Ser Thr Trp Asp Ile Ile Ala Glu Arg  
 195 200 205  
 Leu Gly Phe Met Leu Val Phe Gly Asp Leu Val Trp Ile Pro Phe Ser  
 210 215 220  
 Phe Ser Ile Gln Gly Trp Trp Leu Leu Met Asn Ser Val Glu Leu Thr  
 225 230 235 240  
 Pro Ala Ala Ile Val Ala Asn Cys Phe Val Phe Leu Ile Gly Tyr Met  
 245 250 255  
 Val Phe Arg Gly Ala Asn Lys Gln Lys His Val Phe Lys Lys Asn Pro  
 260 265 270  
 Lys Ala Pro Ile Trp Gly Lys Pro Pro Lys Val Ile Gly Gly Lys Leu  
 275 280 285  
 Leu Ala Ser Gly Tyr Trp Gly Ile Ala Arg His Cys Asn Tyr Leu Gly  
 290 295 300  
 Asp Leu Met Leu Ala Leu Ser Phe Ser Leu Pro Cys Gly Ile Ser Ser  
 305 310 315 320  
 Pro Ile Pro Tyr Phe Tyr Pro Ile Tyr Leu Leu Ile Leu Leu Ile Trp  
 325 330 335  
 Arg Glu Arg Thr Asp Glu Ala Arg Cys Ala Glu Lys Tyr Arg Glu Ile  
 340 345 350  
 Trp Ala Glu Tyr Arg Lys Leu Val Pro Trp Arg Ile Leu Pro Tyr Val  
 355 360 365

Tyr  
 369

<210> 9  
 <211> 430  
 <212> PRT  
 <213> Ascobolus immersus

<400> 9  
 Met Gly Gly Lys Asp Tyr Glu Phe Gly Gly Pro Ile Gly Thr Gly Val  
 1 5 10 15  
 Leu Met Leu Ile Leu Pro Pro Ile Ser His Tyr Leu His Phe Leu Ile  
 20 25 30

7

Gly Trp Trp Gly Val Ala Arg His Val Asn Tyr Phe Gly Asp Trp Ile  
 355 360 365

Met Ala Trp Ser Tyr Cys Leu Thr Thr Gly Phe Asn Thr Pro Leu Thr  
 370 375 380

Tyr Phe Tyr Val Ile Tyr Phe Gly Ile Leu Leu Leu His Arg Asp Arg  
 385 390 395 400

Arg Asp Glu Ala Lys Cys Arg Glu Lys Tyr Gly Lys Asp Trp Asp Arg  
 405 410 415

Tyr Cys Lys Val Val Lys Trp Arg Ile Ile Pro Gly Ile Tyr  
 420 425 430

<210> 10  
 <211> 365  
 <212> PRT  
 <213> Arabidopsis thaliana

<400> 10  
 Met Asp Leu Gly Val Leu Leu Pro Ser Leu Gln Ser Val Tyr Val Leu  
 1 5 10 15

Val Phe Tyr Phe Val Tyr Leu Ala Val Ala Gly Glu Ile Leu Pro Gly  
 20 25 30

Lys Val Ile Arg Gly Val Leu Leu Ser Asp Gly Ser Gln Leu Arg Tyr  
 35 40 45

Arg Cys Asn Gly Leu Leu Ala Leu Ile Leu Leu Val Ala Ile Leu Gly  
 50 55 60

Ile Cys Ala Lys Leu Gly Ile Val Ser Pro Leu Val Val Ala Asp Arg  
 65 70 75 80

Gly Leu Glu Leu Leu Ser Ala Thr Phe Ile Phe Cys Val Leu Val Thr  
 85 90 95

Leu Ala Leu Tyr Val Thr Gly Arg Ser Ser Ser Asn Lys Gly Ser Ser  
 100 105 110

Leu Lys Pro His Val Ser Gly Asn Leu Val His Asp Trp Trp Phe Gly  
 115 120 125

Ile Gln Leu Asn Pro Gln Phe Met Ser Ile Asp Leu Lys Phe Phe Phe  
 130 135 140

Val Arg Ala Gly Met Met Gly Trp Leu Leu Ile Asn Leu Ser Ile Leu  
 145 150 155 160

Ala Lys Ser Val Gln Asp Gly Ser Leu Ser Gln Ser Met Ile Leu Tyr  
 165 170 175

Gln Ile Phe Cys Ala Leu Tyr Ile Leu Asp Tyr Phe Val His Glu Glu  
 180 185 190

Tyr Met Thr Ser Thr Trp Asp Ile Ile Ala Glu Arg Leu Gly Phe Met  
 195 200 205  
 Leu Val Phe Gly Asp Leu Leu Trp Ile Pro Phe Thr Phe Ser Ile Gln  
 210 215 220  
 Gly Trp Trp Leu Leu His Asn Lys Val Glu Leu Thr Val Pro Ala Ile  
 225 230 235 240  
 Val Val Asn Cys Leu Val Phe Leu Ile Gly Tyr Met Val Phe Arg Gly  
 245 250 255  
 Ala Asn Lys Gln Lys His Ile Phe Lys Lys Asn Pro Lys Thr Pro Ile  
 260 265 270  
 Trp Gly Lys Pro Pro Val Val Val Gly Gly Lys Leu Leu Val Ser Gly  
 275 280 285  
 Tyr Trp Gly Ile Ala Arg His Cys Asn Tyr Leu Gly Asp Leu Met Leu  
 290 295 300  
 Ala Leu Ser Phe Ser Leu Pro Cys Gly Ile Ser Ser Pro Val Pro Tyr  
 305 310 315 320  
 Phe Tyr Pro Ile Tyr Leu Leu Ile Leu Leu Ile Trp Arg Glu Arg Arg  
 325 330 335  
 Asp Glu Val Arg Cys Ala Glu Lys Tyr Lys Glu Ile Trp Ala Glu Tyr  
 340 345 350  
 Leu Arg Leu Val Pro Trp Arg Ile Leu Pro Tyr Val Tyr  
 355 360 365